Clinical aspects of exhaled nitric oxide in adults : Associations with atopy, bronchial hyperresponsiveness, smoking and chronic obstruction by Rouhos, Annamari
 
 
 
 
Division of Clinical Physiology and Nuclear Medicine, Laboratory Department 
Division of Respiratory Diseases, Department of Medicine  
Helsinki University Central Hospital 
Helsinki, Finland 
 
 
 
 
Clinical aspects of exhaled nitric oxide in adults: 
Associations with atopy, bronchial hyperresponsiveness,                               
smoking and chronic obstruction 
 
 
 
 
Annamari Rouhos 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented, with the permission of the Faculty of Medicine of the University of 
Helsinki, for public examination in lecture room 1, Haartman Institute,  
on 11th June 2010, at 12 noon. 
 
Helsinki 2010 
 
 
 
 
Supervised by 
Professor Anssi R.A. Sovijärvi 
Division of Clinical Physiology and Nuclear Medicine 
Laboratory Department 
Helsinki University Central Hospital 
 
Docent Jouko Karjalainen 
Lastatie 18 A 4 
00660 Helsinki 
 
Reviewed by 
Docent Pekka Malmberg 
Unit of Clinical Physiology 
Skin and Allergy Hospital, Helsinki University Central Hospital 
 
Docent Hannu Kankaanranta 
Department of Pulmonary Medicine 
Seinäjoki Hospital 
 
Official Opponent 
Docent Tarja Laitinen 
Division of Pulmonary Medicine 
Tampere University Central Hospital 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISBN 978-952-92-7381-2 (pbk.) 
ISBN 978-952-10-6294-0 (PDF) 
 
 
Helsinki University Print 
Helsinki 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Knowing is not enough; we must apply. 
Willing is not enough; we must do.  
 
Johann Wolfgang von Goethe (1749–1832)  
 
 
 
 
 
Abstract 
Measurement of fractional exhaled nitric oxide (FENO) has proven useful in assessment 
of patients with respiratory symptoms, especially in predicting steroid response. The 
objective of these studies was to clarify issues relevant for the clinical use of FENO. The 
association between allergic sensitization and FENO among healthy subjects with no signs 
or symptoms of airway diseases was studied in order to assess whether allergic 
sensitization per se influences FENO. The association between airway inflammation and 
bronchial hyperresponsiveness (BHR) in steroid-naive subjects with symptoms suggesting 
asthma was examined, as well as the possible difference in this association between atopic 
and nonatopic subjects. Influence of smoking on FENO was compared between atopic and 
nonatopic steroid-naive asthmatics and healthy subjects. The short-term repeatability of 
FENO in COPD patients was examined in order to assess whether the degree of chronic 
obstruction influences the repeatability, and to assess the clinically significant change in 
FENO in COPD patients.   
For these purposes, we studied a random sample of 248 citizens of Helsinki, 227 army 
conscripts with current symptoms suggesting asthma, 19 COPD patients, and 39 healthy 
subjects. All subjects underwent FENO measurement, spirometry, and histamine and 
exercise challenges; atopy was assessed by skin prick tests. 
Among healthy subjects with no signs of airway diseases, median FENO values were 
similar in skin prick test-positive (13.2 ppb) and -negative (15.5 ppb) subjects (p=0.304), 
with the non-parametric one-tailed 95% upper limit of FENO respectively 29 and 31 ppb. 
In atopic and nonatopic subjects with symptoms suggesting asthma, BHR to histamine 
(HIB) did not significantly differ, but exercise-induced bronchoconstriction (EIB) was 
more severe among atopic subjects (p<0.01). FENO associated with severity of EIB and 
HIB only in atopic patients. FENO in smokers with steroid-naive asthma was significantly 
higher than in healthy smokers and nonsmokers (p=0.001, both comparisons). Among 
atopic asthmatics, FENO was significantly lower in smokers than in nonsmokers 
(p=0.002), but with no difference among nonatopic asthmatics (p=0.89). However, even 
among nonatopic asthmatic smokers, FENO was significantly higher than among healthy 
subjects (p=0.01). In COPD patients, the coefficient of variation (CoV) for measurements 
of FENO repeated after 24 h was 12.4% in COPD patients, and 15.9% in healthy subjects. 
Among COPD patients with GOLD stage 2 disease, the CoV was 13.7%, and among those 
with stage 3 or 4 disease, 10.5%.  
These findings indicate that allergic sensitization per se does not influence FENO, 
supporting the view that elevated FENO indicates NO-producing airway inflammation, 
and that the same reference range can be applied to both skin prick test-positive and -
negative subjects. The significant correlation between FENO and the degree of BHR only 
in atopic steroid-naive subjects with current asthma-like symptoms supports the view that 
the pathogenesis of BHR in atopic asthma is strongly involved in NO-producing airway 
inflammation, whereas in the development of BHR in nonatopic asthma other mechanisms 
may dominate. Attenuation of FENO only in atopic but not in nonatopic smokers with 
steroid-naive asthma may result from differences in the mechanisms of FENO formation 
as well as in the sensitivity of these mechanisms to smoking in atopic and nonatopic 
 
 
 
 
asthma. The results suggest, however, that in young adult smokers, FENO measurement 
may prove useful in assessment of asthmatic airway inflammation. The short-term 
repeatability of FENO in COPD patients with moderate to very severe disease and in 
healthy subjects was equally good. A change in FENO exceeding 24% is likely to reflect a 
significant change in COPD. 
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1 INTRODUCTION 
Asthma and chronic obstructive pulmonary disease (COPD) are common diseases globally 
and in Finland. Asthma affects approximately 6% of the Finnish population (Pallasaho et 
al. 2002), and diagnosed COPD about 5%, with undiagnosed disease estimated to affect a 
further 5% of the population (Laitinen et al. 1999). The prevalence of these diseases is 
increasing due to an increase in allergic sensitization, continued use of tobacco, and aging 
of populations. 
Treatment of asthma by inhaled corticosteroids (ICS) aims at resolution of symptoms 
and optimization of lung function. These indices, however, correlate poorly with airway 
inflammation and bronchial hyperresponsiveness (BHR), the hallmark features of asthma. 
Treatment strategies aiming at reduction of airway inflammation or BHR by monitoring of 
sputum eosinophils (Green et al. 2002a) or monitoring responsiveness to methacholine 
(Sont et al. 1999), in addition to lung function and symptoms, have resulted in better 
asthma control. Unlike asthma patients, only a subset of COPD patients benefit from ICS. 
However, differential diagnosis is not always clear-cut; these diseases may often coexist 
(Marsh et al. 2008), or patients may present with symptoms and findings with features of 
asthma or COPD but not fulfill the diagnostic criteria of either disease. 
Although airway inflammation and bronchial hyperresponsiveness are closely related, 
they represent different aspects of the airway disease, with their relationship possibly 
changing over the course of the disease and its treatment. Atopic and nonatopic asthma 
share these features, but some differences do appear in inflammatory profile and cytokine 
production (Bettiol et al. 2000, Amin et al. 2000, 2005) as well as in the clinical profile of 
the disease (Romanet-Manet et al. 2002). Whether these differences are also reflected in 
the relation between airway inflammation and BHR is unclear. 
Since the first report of increased concentrations of nitric oxide (NO) in the exhaled air 
of asthmatics (Alving et al. 1993), extensive research on fractional exhaled NO (FENO) 
has provided the rationale for its clinical application. FENO correlates with eosinophilic 
airway inflammation, and as eosinophilic inflammation is responsive to steroid treatment, 
FENO may be regarded as a surrogate marker for steroid-responsive airway inflammation 
irrespective of the exact diagnostic label (Taylor et al. 2006). The use of FENO in the 
diagnostic work-up of patients with respiratory symptoms could result in better 
recognition of those with steroid-responsive symptoms, thus helping in focusing 
appropriate treatment on those who are most likely to gain benefit. FENO is easy to 
measure, and the repeatability of the measurement is good in healthy subjects, and in 
subjects with asthma or with respiratory symptoms suggesting asthma (Ekroos et al. 2000, 
2002, Kharitonov et al. 2003). Good repeatability has been reported also in COPD patients 
(Brindicci et al. 2005, Bhowmik et al. 2005, de Laurentiis et al. 2008). However, severe 
obstruction could impair the repeatability; these studies have included only a small 
number of such patients. Further studies are needed before assessment of clinically 
significant changes in FENO in COPD patients during the course of the disease or in 
response to steroid treatment is possible. 
Furthermore, some other aspects of FENO remain unclear or controversial. Reports of 
elevated FENO in subjects with allergic rhinitis without symptoms from the lower 
 
 
 
 
12
respiratory tract or atopic subjects even with no current respiratory symptoms (Horváth & 
Barnes 1999, Franklin et al. 2004, Olin et al. 2006) have inspired criticism of FENO’s 
being merely a feature of atopy rather than of airway inflammation or airway disease. 
Furthermore, smoking has been shown to reduce FENO in healthy and asthmatic subjects 
(Kharitonov et al. 1995a, Verleden et al. 1999, Horváth et al. 2004), compromising the 
clinical value of FENO among smokers.  
The present series of investigations were aimed at examining these unclear issues 
relevant to the clinical use of FENO. Our study of a random sample of citizens of Helsinki 
was part of the large epidemiological FinEsS study (Meren 2005, Pallasaho 2006a, 
Kotaniemi 2006, Kainu 2008), and was aimed at assessing the association between allergic 
sensitization and FENO in healthy asymptomatic nonsmokers with no signs or history of 
airway diseases, and at comparing this association among those with respiratory 
symptoms or diagnosed airway diseases. Studies on steroid-naive army conscripts with 
current symptomatic asthma aimed at establishing the relationship between airway 
inflammation and BHR to both direct and indirect stimuli, as well as the influence of 
smoking on FENO levels, and at assessing whether this relationship differs between atopic 
and nonatopic asthma. In addition, we studied patients with stable COPD to assess 
whether degree of chronic obstruction influences the repeatability of FENO, and to assess 
clinically significant change in FENO in COPD patients.   
 
 
 
 
 
13
2 REVIEW OF THE LITERATURE 
2.1 Exhaled nitric oxide 
2.1.1 Overview 
Nitric oxide (NO), one of the smallest biologically active substances, plays a key role as a 
signal molecule in vital physiologic functions such as regulation of vascular tone and 
modulation of neuronal function, and in host defense. Identification of the endothelium-
derived relaxing factor as NO earned the 1998 Nobel Prize in Physiology or Medicine for 
Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad. In biological tissues, NO is highly 
reactive, whereas in gaseous form it is fairly stable at low concentrations. It differs from 
traditional transmitter molecules as it has no cell membrane receptors and is not stored 
within cells but diffuses freely into the cells. Many of its biological effects are mediated 
by the activation of guanylate cyclase. In addition, NO can interact with transition metals 
such as iron, thiol groups, other free radicals, oxygen, superoxide anion, unsaturated fatty 
acids, and other molecules. Its biological effects depend on its concentration. NO is 
produced by a wide variety of structural and inflammatory cells, including those involved 
in asthma such as eosinophils, mast cells, epithelial cells, macrophages, and smooth 
muscle cells (Moncada et al. 1991, Yates 2001a).  
NO is formed endogenously from the amino acid L-arginine in a reaction catalyzed by 
nitric oxide synthase (NOS). Three isoforms of NOS have been identified: endothelial 
NOS (eNOS or NOS1), neuronal NOS (nNOS or NOS3), and inducible NOS (iNOS or 
NOS2). The first two, referred to as constitutive NOS (cNOS), are responsible for the 
physiological production of NO, yielding picomolar concentrations within seconds or 
minutes in response to small rises in intracellular calcium concentration secondary to cell 
activation. These low concentrations of NO regulate vascular tone, inhibit platelet 
aggregation, and act as a transmitter in the non-adrenergic-non-cholinergic nerve endings 
regulating various respiratory, gastrointestinal, and genitourinary functions (Moncada et 
al. 1991, Yates 2001a). NO is important for the normal beating of airway epithelial cilia, it 
also affects mucus secretion and plasma exudation and thus has an influence on 
mucociliary clearance (Jain et al. 1993, Yates 2001a).  
Activation of the inducible isoform of NOS (iNOS) results in production of much 
larger amounts of NO in nanomolar concentrations for longer periods of time after cell 
activation. Its activity is independent of calcium concentration and is regulated by 
transcription factors, most importantly by nuclear factor kappa B (NF-κB), which is 
activated by several proinflammatory cytokines, especially tumor necrosis factor-alfa 
(TNF-α) and interferon-gamma (IFN-γ), or microbial products (Yates 2001a, Korhonen et 
al. 2005). NO derived from epithelial cells and macrophages may be important in the 
pulmonary host defense mechanism because of its antimicrobial activity (Nathan & Hibbs 
1991, Yates 2001a). Increased FENO production may have an amplifying effect on airway 
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inflammation, as NO can facilitate eosinophil chemotaxis to the airways or can enhance 
eosinophil viability (Korhonen et al. 2005).  NO may also promote the development of 
Th2 responses, because it reduces IFN-γ production, thus allowing proliferation of Th2 
lymphocytes (Yates 2001a). The formation and effects of NO in airway inflammation are 
presented in Figure 1. The gene for iNOS is located in chromosome 17q11.2-q12 in a 
region where a linkage with atopy and asthma has been reported, and polymorphisms in 
the iNOS gene have been reported to associate with severity of asthma and with 
eosinophilia (Batra et al. 2007). 
After its production, NO can be exhaled, metabolized to nitrate and nitrite, or can 
interact with superoxide to form peroxynitrite. NOS is not the only source of NO, as NO 
can also be generated nonenzymatically from several chemical sources such as S-
nitrosothiols and organic nitrates (Marteus et al. 2005). NO is produced along the entire 
airway, with hundred-fold higher concentrations derived from upper than lower airways, 
with most of the NO from the upper airways produced in the nasal cavities (Lundberg et 
al. 1996). This large NO production in the upper airways has to be taken into account in 
the measurement technique in order to obtain NO levels representative of NO production 
in the lower airways. 
 
 
 
 
Figure 1 Formation and effects of NO in airway inflammation (modified from Kharitonov & 
Barnes 2001) 
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2.1.2 FENO and airway inflammation 
The beginning of NO research in airway pathology can be attributed to the report by 
Gustafsson and co-workers in 1991 demonstrating that endogenous nitric oxide can be 
measured in the exhaled air of experimental animals and humans. A higher amount of 
exhaled NO in atopic asthma than in healthy subjects was first reported in 1993 (Alving et 
al. 1993), followed by the finding of iNOS expression in the bronchial biopsies of 
nonsmoking steroid-naive atopic asthmatics, whereas it was almost absent in healthy 
subjects (Hamid et al. 1993). Furthermore, normal bronchial epithelial cells were found to 
express iNOS in response to stimulation with a cytokine, TNF-α (Hamid et al. 1993). An 
inhaled allergen challenge in asthmatic patients has been shown not to change FENO 
during the acute bronchoconstriction, but instead, a progressive increase during the late 
response has been detectable, suggesting increased iNOS expression and consequently 
increased NO production in response to inflammatory cytokines (Kharitonov et al. 1995b).  
As increased levels of FENO have appeared especially in asthmatics, numerous studies 
have examined the correlation between FENO and airway inflammation assessed directly 
in induced sputum, or bronchoalveolar lavage (BAL), or in endobronchial biopsies in 
patients with asthma (Jatakanon et al. 1998, Horvath et al. 1998, Lim et al. 1999, 
Piacentini et al. 1999, Jatakanon et al. 2000, Berlyne et al. 2000, Lim et al. 2000, van den 
Toorn et al. 2001, Payne et al. 2001, Grönke et al. 2002, Jones et al. 2002, Warke et al. 
2002, Berry et al. 2005, Malmberg et al. 2005). In order to evaluate the use of FENO as a 
surrogate marker for eosinophilic airway inflammation in clinical practice, the greatest 
interest has been focused on studies examining the association between sputum 
eosinophilia and FENO. A significant correlation between FENO and sputum eosinophils 
has been detectable in several studies (Jatakanon et al. 1998, Horvath et al. 1998, 
Piacentini et al. 1999, Jatakanon et al. 2000, Berlyne et al. 2000, Jones et al. 2002, Grönke 
et al. 2002, Berry et al. 2005, Malmberg et al. 2005), the largest study being by Berry and 
co-workers (2005), in which a significant correlation appeared between FENO and sputum 
eosinophil count in a study population of 566 stable asthmatics. In general, the strongest 
associations have appeared among nonsmoking steroid-naive subjects with atopic asthma. 
2.1.3 Measurement of FENO 
Exhaled nitric oxide can be measured by a chemiluminescence method based on the 
photochemical reaction between NO and ozone (03) generated in the analyzer. The amount 
of light emitted in the reaction, quantified by a photomultiplier, is proportional to the 
amount of NO in the exhaled air. The result is expressed as a fractional concentration, 
parts per billion (ppb). Measurements are usually performed online, meaning FENO 
testing with a real-time display of NO breath profiles. Off-line measurements, meaning the 
collection of exhalate into a suitable reservoir for delayed analysis, are also possible but 
seldom used, because commercial portable hand-held analyzers using a rapid 
electrochemical method have become available. The repeatability of FENO measurements 
using a hand-held device has been shown to be good (Takalo et al. 2008). Some 
differences in FENO results have been reported between different stationary analyzers 
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(Borrill et al. 2006), whereas agreement has been good between measurements with hand-
held and stationary devices (Alving et al. 2006, Khalili et al. 2007). Most 
chemiluminescence analyzers are sensitive to < 1 ppb of NO.  
For the measurement, the subject is instructed to exhale from near-total lung capacity 
against a flow resistor in order to close the soft palate and to avoid any contamination 
from the high NO content of the nasal cavities. NO-free air (filtered room air, synthetic air 
or 100% oxygen) is used for inhalation in order to avoid the influence of variations in 
ambient air NO. Because breath-holding may elevate FENO, exhalation should then start 
immediately, and it should last at least 6 seconds in order to allow the airway 
compartment to be washed out and a reasonable plateau to be achieved. The plateau 
concentration of FENO is defined as the mean concentration over a 3-second period 
during the stable end-expiratory plateau. The exhalation procedure is repeated at least 
twice, reproducible exhalations yielding plateau NO values that agree within 10%. The 
result of the measurement is the mean of the plateau NO values of these repeated 
measurements. When standardized techniques have been used, the repeatability of FENO 
measurements has been good in healthy subjects (Ekroos et al. 2000, Kharitonov et al. 
2003), both in nonsmokers and smokers (Bohadana 2008), in asthma (Ekroos et al. 2002, 
Kharitonov et al. 2003), and in subjects with asthma-like respiratory symptoms (Ekroos et 
al. 2002). Good repeatability has been reported also in patients with COPD (Brindicci et 
al. 2005, Bhowmik et al. 2005, de Laurentiis et al. 2008), but these studies have included 
only a small number of patients with severe disease. Severe obstruction may impair the 
subject’s ability to maintain the required flow or impair the diffusion of NO into the 
exhaled air due to collapse of the bronchioles during exhalation. These issues must be 
addressed for clinical use of FENO measurements in assessment of eosinophilic 
inflammation or steroid response in COPD patients.  
2.1.4 Factors influencing FENO 
Exhalation flow rate is crucial for obtaining reproducible measurement. Increase in flow 
rate results in decrease in exhaled NO concentration, as faster air flow through the 
bronchial tree leaves less time for diffusion of NO from bronchial mucosa to the exhaled 
air. Following the initial reports on increased FENO in asthma, a wide range of different 
techniques have been used, and great efforts made to standardize the method. Three sets of 
guidelines have been published: the first one by European Respiratory Society (ERS) in 
1997 (Kharitonov et al. 1997), which recommended a flow rate of 10 to 15 l/min (167-250 
ml/s). This was followed by the American Thoracic Society (ATS) guidelines in 1999 
(American Thoracic Society 1999) and combined ATS/ERS recommendations in 2005 
(ATS/ERS 2005), both of which chose a flow rate of 50 ml/s as a reasonable compromise 
between measurement sensitivity and patient comfort. For reproducible measurements, the 
variation in flow rate must remain between 45 and 55 ml/s during the time of the NO 
plateau generation. Measurements with multiple flow rates can be applied to differentiate 
between alveolar and bronchial components of FENO (Lehtimäki 2003, Barnes et al. 
2006).  
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Spirometric maneuvers (Deykin et al. 1998, Silkoff et al. 1999, Deykin et al. 2000) and 
bronchial challenges with direct and indirect stimuli (de Gouw et al. 1998) and sputum 
induction with hypertonic saline (Beier et al. 2003) may transiently reduce FENO, and it is 
thus advisable they be performed after FENO measurements (ATS/ERS 2005). The FENO 
maneuver itself does not influence FENO levels (Silkoff et al. 1999). Non-enzymatic 
production of NO in the oral cavity may influence FENO. Mouth rinsing with an alkaline 
solution such as sodium bicarbonate or with an antibacterial mouth wash before the 
measurement has been reported to rapidly and transiently reduce FENO (Zetterqvist et al. 
1999, Marteus et al. 2005), but the duration of this effect is unclear. Current guidelines do 
not advise on mouth rinsing before FENO measurement (ATS/ERS 2005). The influence 
on FENO of prior caffeine consumption is controversial (Taylor et al. 2004), alcohol may 
cause a slight decrease (Yates et al. 1996, Jones et al. 2005), and ingestion of nitrite or 
nitrate-rich foods a slight increase in FENO (Zetterqvist et al. 1999); thus patients are 
instructed to refrain from eating and drinking anything for one hour before FENO 
measurements (ATS/ERS 2005). Influence on FENO of active and passive smoking and 
smoking cessation is addressed in section 2.6. Respiratory tract infections may raise 
FENO, with return to baseline level reported after 3 weeks (Kharitonov et al. 1995c, 
Murphy et al. 1998). Most studies, although not all, have found no circadian rhythm in 
FENO, making it uncertain whether measurements need to be standardized for time of day 
(ATS/ERS 2005). 
Short-acting β2-agonists (SABA) may cause a slight, transient increase in FENO 
(Yates et al. 1997, Silkoff et al. 1999), whereas no influence has been detectable with 
long-acting β2-agonists (LABA) (Yates et al. 1997). Steroid treatment has no inhibitory 
influence on the physiological NO production by constitutive NOS, whereas the increased 
FENO in asthma produced by iNOS activity is dose-dependently reduced by steroid 
treatment (Kharitonov et al. 1996a, Jatakanon et al. 1999a, Jones et al. 2002, Kharitonov et 
al. 2002). This may be due to inhibition of iNOS expression, or inhibition of synthesis of 
proinflammatory cytokines as well as reduction in the number of activated cells that 
release proinflammatory cytokines in the airways (Kharitonov et al. 1996a). The 
leukotriene receptor-antagonist montelukast (Bisgaard et al. 1999, Sandrini et al. 2003) 
and the monoclonal anti-IgE antibody omalizumab (Silkoff et al. 2004) reduce FENO in 
patients with asthma. Neither nedocromil (Carra et al. 2001) nor theophylline (Lim et al. 
2001) has been found to reduce FENO.  
The effects of gender, height or age on FENO have been conflicting. Several studies 
have reported lower concentrations in females, even when adjusted for height or weight 
(Tsang et al. 2001, Olivieri et al. 2006, Taylor et al. 2007, Travers et al. 2007), whereas 
others have found no difference between genders when other anthropometric factors are 
taken into account  (Olin et al. 2006, 2007). Studies by Travers and by Taylor reported 
gender, atopy, and smoking status to influence FENO. The largest study, involving 3 376 
adults, found FENO levels to be dependent on age and height, independent of gender 
(Olin et al. 2007), and defined the upper limit of FENO as ranging from 24 to 54 ppb. A 
summary of some suggested reference values in healthy adults is given in Table 1. 
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Table 1. Summary of some suggested reference values for FENO 
Authors
Upper limit of 
reference value (ppb) Subjects
Flow rate 
(ml/s) Comments
Ekroos et al. 2000* < 12
adult 
nonsmokers 90-120 
Olin et al. 2007 24.0-54.0
adult 
nonsmokers 50
equation: Ln (FENO) = 
0.057 + 0.013 x height (cm) 
+ 0.0088 x age (yrs)
Travers et al. 2007 < 41.1 adults 50
* presented for interpretation of the results in Studies II and III  
 
 
Not only is eosinophilic inflammation or asthma known to influence FENO. Increased 
FENO levels have been reported in other inflammatory lung diseases such as allergic 
alveolitis, fibrosing alveolitis, bronchiectasis, bronchiolitis obliterans syndrome in lung 
transplants, and decreased levels in cystic fibrosis and in primary ciliary dyskinesia, as 
well as in pulmonary hypertension; in sarcoidosis results are conflicting (Kharitonov & 
Barnes 2001). FENO in COPD is addressed in section 2.5.  
2.2 Atopy 
2.2.1 Overview 
The word “atopy,” coming from the Greek, meaning “special” or “unusual,” was 
introduced in 1923 (Coca & Cooke 1923). Atopy was considered to be hereditary, limited 
to a small group of patients, clinically characterized by hay fever and bronchial asthma, 
and associated with immediate-type (wheal-and-flare) skin reactions. The current 
definition of atopy as proposed by the Nomenclature Review Committee of the World 
Allergy Organization reads as follows: “Atopy is a personal and/or familial tendency to 
become sensitized and produce IgE antibodies in response to ordinary exposures to 
allergens, usually proteins. As a consequence, these persons can develop typical 
symptoms of asthma, rhinoconjunctivitis, or eczema” (Johansson et al. 2004). A 2001 
position paper from the European Academy of Allergology and Clinical Immunology 
(EAACI) recommended that “a healthy asymptomatic person with a positive skin prick 
test or the presence of specific IgE antibodies should be referred to as “skin prick test-
positive” or “IgE sensitized,” and the term atopic reserved for a person with this 
predisposition who is suffering from typical allergic symptoms” (Johansson et al. 2001), 
whereas the revised nomenclature report concludes that “atopy is a clinical definition of an 
IgE-antibody high-responder, and allergic symptoms in a person of the atopic constitution 
may be referred to as atopic, as in atopic rhinitis” (Johansson et al. 2004). According to 
this recommendation, also the term “atopic dermatitis,” which is frequently used to 
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describe eczema with certain clinical characteristics, should be restricted to those in whom 
IgE-sensitization can be detected (Johansson et al. 2004). 
Atopy is a hereditary trait: If both parents are atopic, the risk of child’s developing an 
IgE-mediated allergy is 40 to 60%. If neither parent is atopic, the risk used to be 
considered 5 to 10%, but the percentage is increasing (Johansson et al. 2001). 
Associations have been found between several gene loci and asthma and high IgE levels 
(Laitinen et al. 2001), but no specific genetic markers for atopy have been identified, 
suggesting that atopy is a polygenic disorder (Johansson et al. 2001). Recent studies have 
reported mutations in the filaggrin-protein gene as resulting in impaired skin barrier 
function predisposing to atopic dermatitis and asthma (Holloway et al. 2010). The wide 
range in reported prevalence rates of atopic sensitization may depend on the study 
populations, differences in performing skin prick tests and reading the reactions, 
differences between allergens and in the potency of allergenic extracts (Baldacci et al. 
2001). The prevalence of atopic sensitization in Helsinki, Finland, as based on skin prick 
test results, has been reported to be high, with 57% of subjects aged 26 to 39 being 
sensitized to at least one allergen, and 42% of those sensitized responding to at least four 
allergens (Pallasaho et al. 2006b). However, approximately 40% of the skin prick test-
positive subjects in the Finnish adolescent population have been asymptomatic (Haahtela 
et al. 1980, Kilpeläinen et al. 2001).  
Atopic sensitization is not a sign of a disease, but it bears the risk for development of 
typical allergic diseases such as allergic rhinitis or asthma. Skin prick test-positive 
subjects have been reported to be about three times as likely to develop asthma, and have 
more than twice the risk for allergic rhinitis of skin prick test-negative subjects (Settipane 
et al. 1994). Multiple sensitization carries further increased risk, and it associates strongly 
with physician-diagnosed asthma, wheezing, and allergic rhinoconjunctivitis (Pallasaho et 
al. 2006b). The presence of atopy may facilitate the development of exercise-induced 
bronchoconstriction (EIB). The degree of atopic sensitization indicated by atopy score has 
been shown to correlate significantly with degree of EIB (Koh et al. 2002). The Koh study 
used an extensive panel of 53 allergens and defined as a positive response a wheal size of 
≥ 4 mm.  
 
2.2.2 Assessment of atopy  
Atopic sensitization can be assessed either by skin prick test or by measurement of IgE in 
a blood sample. Allergen-specific IgE is preferable to total IgE, which is significantly 
influenced by age, sex, smoking habits, and ethnicity (Baldacci et al. 2001). Allergen-
specific IgE in a blood sample is considered positive if the level is higher than the lowest 
detection limit of the assay. In the skin prick tests, an interaction is artificially created 
between the allergen and the IgE bound to mast cell receptors in the skin. The selection of 
a reaction size regarded as positive is a compromise between acceptable levels of 
sensitivity and specificity. Usually a reaction size ≥ 3 mm in diameter is considered 
positive, and subjects with at least one positive reaction regarded as skin prick test-
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positive (Dreborg 1989, Dreborg & Frew 1993). A decrease occurs in skin prick test 
reactivity with aging (Barbee et al. 1981), due to either a real decline in immunologic 
reactivity because of aging or to a decrease in the ability of the skin to react to 
immunological challenges (Baldacci et al. 2001). Dermographismus, present in 3 to 5% of 
the population, prevents interpretation of skin test results.  
The number of allergens or specific IgEs required for a panel allowing identification of 
all atopic subjects in a population is uncertain. The NHANES 2005-2006 study reported 
that approximately 92% of atopic subjects were identifiable by six specific IgEs, but to 
increase identification to more than 99% required eleven specific IgEs (Gergen et al. 
2009). The ERCHS study on 20- to 44-year-olds concluded that seven allergens in a skin 
prick test panel would identify almost all the sensitized subjects (Bousquet et al. 2007), 
but their definition of a positive response as a wheal size > 0 mm differs from the 
guidelines. This cut-off level of > 0 mm, however, has been assessed in a recent study to 
be best at identifying those with allergen-specific IgE in epidemiological studies 
(Bousquet et al. 2008). In addition to the dichotomized results, the quantification of 
allergic sensitization has also been applied based on atopy score by summing up the wheal 
diameters of each positive reaction (Miles et al. 1995, Koh et al. 2002) or by summing up 
specific IgE values (Söderström et al. 2003).  
 
2.2.3 Atopy and FENO 
Whether atopic sensitization per se, without the manifestation of any allergic airway 
disease, may lead to increased FENO has been a matter of debate. Studies based on 
general population samples have generally found FENO to be higher in atopic than in 
nonatopic subjects (Salome et al. 1999, Franklin et al. 2004, Olin et al. 2006), and atopic 
subjects without asthma or asthma-like symptoms but with allergic rhinitis have also 
shown increased levels of FENO (Henriksen et al. 1999, Gratziou et al. 1999). Study of a 
heterogeneous population of 115 subjects found higher FENO levels in skin prick test-
positive than in skin prick test-negative subjects (Franklin et al. 2004). Although all 
subjects were asymptomatic at the time of the study, 26% had physician-diagnosed 
asthma, 17% reported wheezing during the previous year, and 17% had increased 
bronchial responsiveness; thus they did not represent a healthy population. A large 
general-population study found atopy as being a significant predictor of FENO even after 
exclusion of subjects with asthma or current asthma symptoms during the previous month 
(Olin et al. 2006). However, this study population also included subjects with a history of 
chronic or recurrent respiratory symptoms, and atopy was defined by measuring total IgE. 
Horváth and Barnes (1999) found higher levels of FENO in skin prick test-positive than in 
skin prick test-negative healthy asymptomatic subjects. The majority of the 15 atopic 
subjects included in the study, however, had mild to moderate bronchial 
hyperresponsiveness on methacholine challenge.  
Salome and co-workers (1999) found higher FENO in skin prick test-positive than in 
skin prick test-negative young adults without current symptoms (wheeze within 12 
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months) or bronchial hyperresponsiveness in histamine challenge. In that study, however, 
the flow rate of FENO measurement was not controlled, thus influencing the results. In 
contrast, no significant difference in FENO was reported between 28 skin prick test-
positive and 22 skin prick test-negative healthy subjects with no symptoms or signs of 
airway disease, no signs of airway obstruction in spirometry, and no bronchial 
hyperresponsiveness in methacholine challenge (Berlyne et al. 2000). Equal FENO levels 
have also been detectable in 20 skin prick test-positive and 80 skin prick test-negative 
healthy asymptomatic adults with no history of respiratory symptoms suggesting asthma 
or rhinitis (Gratziou et al. 1999). A similar finding was also reported by Olin and co-
workers (2004) in a predominantly male population of 33 IgE-sensitized and 137 non-IgE-
sensitized bleachery workers with no reported asthma or rhinitis.  
2.3 Bronchial hyperresponsiveness 
2.3.1 Overview 
 
Bronchial hyperresponsiveness (BHR) can be defined as “an increase in the ease and 
degree of airway narrowing to inhaled bronchoconstrictor stimuli of chemical or physical 
origin, leading to variability in airway obstruction” (Sterk 1993a). Bronchoconstrictor 
stimuli are classified according to the main mechanism through which they induce airway 
limitation. Direct stimuli such as histamine and methacholine act directly on bronchial 
smooth muscle, causing it to contract and the airways to narrow. Indirect airway 
challenges such as exercise, adenosine monophosphate (AMP), and mannitol induce 
airflow limitation by acting on intermediary cells, which upon stimulation release 
mediators that provoke smooth muscle contraction and cause secondary 
bronchoconstriction (Sterk et al. 1993b).  
BHR has been hypothesized to involve two at least semi-independent components: the 
relatively fixed or persistent BHR and superimposed on this a component of variable or 
episodic BHR (Cockroft & Davis 2006). The variable component is likely to be closely 
associated with airway inflammation and to be reflected by indirect bronchial challenges, 
whereas the underlying persistent component appears related to structural airway changes, 
collectively referred to as airway remodeling. This includes subendothelial basement 
membrane deposition of collagen, airway smooth muscle hypertrophy or hyperplasia, or 
both, increased vascularity, and changes in extracellular matrix composition, leading to 
increased contractility of the airway smooth muscle and increased airway wall thickness. 
This persistent component of BHR may be slowly or incompletely responsive to anti-
inflammatory therapy, and is likely to be better reflected by direct bronchial challenges 
(Cockroft & Davis 2006). 
Given this background, although BHR to direct stimuli may already show 
improvement after a few days’ treatment with inhaled steroids (ICS) in mild asthma 
 
 
 
 
22
(Sovijärvi et al. 2003), BHR continues to improve with prolonged steroid treatment for at 
least one year (van Schoor et al. 2005), and some degree of BHR may remain even during 
long-term treatment with ICS (Brannan et al. 2007). In contrast, BHR to indirect 
challenges has been shown to be more sensitive to ICS, because it appears to be related to 
concentration of mast cells and eosinophils in the airway (Brannan et al. 2007). In a study 
on atopic asthma and steroid treatment, multiple regression analysis explained 40% of the 
variability in BHR: 21% related to reticular basement membrane thickening, 11% related 
to BAL epithelial cells, and 8% to BAL eosinophils (Ward et al. 2002). The Ward study 
concluded that airway inflammation and remodeling in asthma are interrelated, and 
improvement is achieved with ICS, but the changes are not temporally concordant; thus 
prolonged treatment may be necessary for maximal benefit (Ward et al 2002). To what 
extent each of these components, persistent and variable, influence BHR may change 
during the course of the disease, as airway inflammation is suggested to precede structural 
changes, which may represent a consequence of a chronic airway inflammation. A study 
on 66 nonsmoking steroid-free subjects with mild to moderate atopic asthma found the 
relationship between airway inflammation and BHR to depend on the asthma duration: a 
significant correlation emerged between FENO and BHR to methacholine in patients with 
duration of the disease ≤ 16 years, whereas no significant correlation appeared between 
these parameters in subjects with longer-duration disease (Grönke et al. 2002).  
Bronchial hyperresponsiveness is not specific for asthma; mild BHR may be present 
also in COPD as well as in smokers. Asymptomatic BHR has been demonstrated in 
epidemiological studies, being more frequently observed in subjects with atopy, in 
members of families with asthma, in those exposed to tobacco smoke, and in women 
(Boulet 2003). Its significance is uncertain, as some follow-up studies have found it to be 
a risk factor for development of asthma (Laprise et al. 1997, Brutsche et al. 2006), 
whereas some have not (van den Nieuwenhof et al. 2008). 
2.3.2 Assessment of bronchial hyperresponsiveness 
2.3.2.1 Direct bronchial challenges 
Direct airway challenges cause airflow limitation by acting directly on effector cells, 
predominantly on airway smooth muscle but also on mucus glands and on airway 
microvasculature without involving intermediate pathways. Direct stimuli include 
cholinergic agonists (methacholine, acetylcholine, carbachol), histamine, prostaglandin D2 
and leukotrienes C4, D4 and E4, with histamine and methacholine as the agents most 
widely used (Sterk et al. 1993b). Response to the challenge is usually presented as a 
provocative dose (PD) or concentration (PC) that produces a 15 or 20% fall in FEV1, for 
example PD15FEV1 signifying the provocative dose required to induce a reduction of 15% 
in FEV1. Responsiveness to histamine and to methacholine has correlated significantly 
with each other (Juniper et al. 1978, Juusela et al. 2008). The direct challenges have high 
sensitivity for the diagnosis of asthma and will consequently identify most cases of 
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asthma, even the mild cases. Direct challenges are more useful in excluding a diagnosis of 
asthma than in establishing one because their negative predictive power is greater than 
their positive predictive power; thus a negative response in general can be used to rule out 
asthma (Crapo et al. 2000). However, the sensitivity and the specificity of the tests 
naturally depend on the defined cut-off levels. 
2.3.2.2 Indirect bronchial challenges 
Indirect airway challenges induce airflow limitation by acting on cells other than smooth 
muscle cells, for instance, inflammatory cells, epithelial cells, and neuronal cells which 
upon stimulation release mediators, cytokines, or neurotransmitters that provoke smooth 
muscle contraction and cause secondary bronchoconstriction. A wide array of mediators 
are involved (histamine, leukotrienes, prostaglandins, acetylcholine, tachykins, 
neuropeptides). Because the responses to these challenges are modified or even 
completely inhibited by ICS, the airway response to these challenges may more closely 
reflect active airway inflammation (Joos et al. 2003). Indirect stimuli include physical 
stimuli such as exercise, nonisotonic aerosols (hyper- and hypotonic saline, distilled water, 
mannitol), eucapnic voluntary hyperventilation of dry air, and pharmacological stimuli 
such as adenosine monophosphate (AMP), tachykins, bradykinin, metabisulphite/SO2, 
and propranolol (Joos et al. 2003). In clinical practice, exercise is the most widely applied 
indirect stimulus, with use of mannitol probably increasing, now that mannitol capsules 
and a dry powder inhaler have become commercially available. Eucapnic voluntary 
hyperventilation is also useful in clinical practice. AMP has been used widely in clinical 
studies.  
Several mechanisms are involved in bronchoconstriction induced by indirect stimuli 
(Figure 2). Exercise causes loss of water via evaporation from the mucosal lining of the 
airway surfaces, which results in osmotic (increase in airway osmolarity) effects, which in 
turn stimulate the release of bronchoconstrictor mediators mainly from mast cells and 
epithelial cells (Joos et al. 2003). Increased urinary levels of mast cell markers have been 
detectable in association with exercise-induced bronchoconstriction (EIB) in asthmatics 
(O’Sullivan et al. 1998). Vascular mechanisms caused by thermal effects (cooling and 
rewarming) may contribute to bronchoconstriction independent of the release of mediators 
(McFadden 1994).  In addition, changes in airway osmolarity and temperature, as well as 
the mediators released may also directly activate neural pathways, resulting in reflex 
bronchoconstriction and increased microvascular permeability and edema (van Schoor et 
al. 2000). The same mechanisms act in eucapnic voluntary hyperventilation of dry air 
(Brannan et al. 2007). As for nonisotonic aerosols, their osmolarity appears to be the most 
important determinant of the airway response (van Schoor 2000). AMP enhances the 
release of a variety of inflammatory mediators from mast cells, exerting its action through 
interaction with specific adenosine receptors, one subtype being present on the surface of 
mast cells (van Schoor et al. 2005).  
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Figure 2 Mechanisms of indirect and direct bronchial challenges (modified from Brannan et 
al. 2007) 
Exercise is considered to be the most physiological of all stimuli used for challenge 
testing. The major factors determining the occurrence and severity of exercise-induced 
bronchoconstriction (EIB) are the level of the ventilation, the water content and the 
temperature of the inspired air during the exercise, and the interval since exercise last 
induced an attack of asthma. Usually the most sensitive way of provoking exercise-
induced bronchoconstriction in adult subjects is for them to exercise for 8 minutes at an 
intensity that raises the minute ventilation to 40 to 60% of the predicted maximum 
voluntary ventilation (Crapo et al. 2000, Joos et al. 2003). In the absence of a measure of 
ventilation, as often is the case in a clinical setting, one substitute is a heart-rate target for 
which 80 to 90% of the predicted maximum should be reached and maintained for the last 
4 minutes of the exercise (Crapo et al. 2000, Joos et al. 2003). The most effective exercise 
is hard and brief, and the target exercise intensity should be reached within 4 minutes, 
because the prolonged warm-up period may induce refractoriness to EIB (Crapo et al. 
2000). Appropriate post-exercise testing should include measurements 5, 10, 15, 20, and 
30 minutes after cessation of exercise (Crapo et al. 2000). The maximal airflow limitation 
is usually detected within 3 to 12 minutes after exercise, with spontaneous recovery within 
30 minutes (van Schoor et al. 2000). The criterion for a positive response is controversial: 
a reduction in FEV1 of 10% or more of the pre-exercise value is generally considered 
abnormal (Crapo et al. 2000, Joos et al. 2003), whereas some authors suggest that a value 
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of 15% is more diagnostic of asthma, particularly if exercise has been performed in the 
field. However, a fall in FEV1 of 10% has been considered a reasonable criterion, because 
healthy subjects generally demonstrate an increase in FEV1 after exercise (Crapo et al. 
2000). The preferred modes of exercise are treadmill or cycle ergometer, but free-range 
running has been considered useful for screening populations (Crapo et al. 2000).  
As all the indirect challenges are thought to work by similar mechanisms, the 
responses to indirect challenges can be expected to show good mutual correlation. Those 
asthmatics with a positive response to exercise, AMP, or hypertonic saline have been 
shown to be positive to mannitol, and asthmatics positive to saline and mannitol have been 
positive to eucapnic voluntary hyperpnoea (Brannan et al. 2007). In mild cases, indirect 
challenges will often be negative, whereas a positive response to indirect challenge is 
highly specific to asthma. Indirect challenges may be better suited to assess therapeutic 
efficacy and short-term changes in asthma control than direct challenges (Joos et al. 2003). 
Exercise is the bronchial challenge test that most closely resembles the circumstances of 
everyday life of an asthmatic subject. Although not very sensitive, an exercise test is 
highly specific for the diagnosis of asthma, and is particularly useful in children, army 
recruits, and athletes (van Schoor et al. 2000).  
Direct and indirect challenges may have an influence on each other. When performed 
after a methacholine challenge, the response to a mannitol challenge has been attenuated, 
but when these two challenges were performed in the opposite order, the mannitol 
challenge had no influence on responsiveness to methacholine (Gade et al. 2009). 
Methacholine challenge has also been reported to blunt the response to subsequent 
eucapnic voluntary hyperventilation (Hurwitz et al. 1994). A repeated or continued 
exercise challenge can induce tachyphylaxis: 50% of patients are refractory to a second 
exercise challenge performed within 60 minutes. Most lose this refractory state within 2 
hours, but this occasionally takes as long as 4 hours (Crapo et al. 2000). Similarly, 
repeated inhalation of AMP induces airway refractoriness. This refractoriness is likely to 
be mediated through depletion of the mediators involved in bronchoconstriction (van 
Schoor et al. 2000). Exercise challenge has had no influence on airway inflammation, as 
assessed by induced sputum (Tateishi et al. 1996, Gavreau et al. 2000) or by FENO 
(Scollo et al. 2000, El-Halawani et al. 2003). 
2.3.3 Bronchial hyperresponsiveness, airway inflammation and FENO 
If BHR is a combination of persistent BHR related to permanent or somewhat permanent 
structural changes, and of variable BHR, more related to the inflammatory component, it 
is understandable that the findings of the relationship between BHR and airway 
inflammation have been inconsistent. Some studies have reported significant correlations 
between eosinophilic inflammation assessed by sputum eosinophils or by FENO 
measurement and BHR to direct stimuli (Dupont et al. 1998, Jatakanon et al. 1998, Lim et 
al. 1999, Salome et al. 1999, Warke et al. 2002, Langley et al. 2003, Zietkowski et al. 
2006); but some others none (Crimi et al. 1998, Yoshikawa et al. 1998, van Rensen et al. 
1999, Polosa et al. 2000, Ichinose et al. 2000, Leuppi et al. 2001, Prieto et al. 2002a). 
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When BHR has been assessed by indirect challenges in study populations of steroid-naive 
subjects, correlations between these parameters have often been significant (Yoshikawa et 
al. 1998, Polosa et al. 2000, Prieto et al. 2002a, Berkman et al. 2005, Porsbjerg et al. 
2007). If a significant correlation has appeared between eosinophilic airway inflammation 
and BHR in steroid-naive subjects, the correlation is often lost when steroid-treated 
subjects have been studied (Dupont et al. 1998, Lim et al. 1999, Leuppi et al. 2001). 
Despite improvement in eosinophilic inflammation and in BHR during steroid treatment, 
or during decreased exposure to allergens, no significant correlation between these 
changes has been detected (van Rensen et al. 1999, Prieto et al. 2002b). This reflects the 
fact that improvements in various aspects of airway pathology are not directly related to 
each other and cannot be interpreted interchangeably.  
A further discrepancy in the correlation studies can be caused by the subjects’ atopic 
status. Most of the studies have involved only atopic subjects (Jatakanon et al. 1998, Crimi 
et al. 1998, van Rensen et al. 1999, Polosa et al. 2000, Leuppi et al. 2001, Grönke et al. 
2002, Prieto et al. 2002a, 2002b) or mixed populations comprising mainly atopic subjects 
(Yoshikawa et al. 1998, Scollo et al. 2000, Langley et al. 2003), and the atopic status is 
not always even assessed (Ichinose et al. 2000, Berkman et al. 2005), or the results have 
not been presented separately for atopic and nonatopic subjects (Dupont et al. 1998, 
Langley et al. 2003, Porsbjerg et al. 2007). Data on comparative studies assessing the 
correlation between airway inflammation and BHR separately in atopic and nonatopic 
subjects are very limited (Lúdvíksdóttir et al. 1999, Zietkowski et al. 2006). 
Lúdvíksdóttir’s study found a significant correlation between FENO and BHR to 
methacholine in atopic but not in nonatopic subjects, whereas the study by Zietkowski and 
co-workers found significant correlations among both atopic and nonatopic subjects, the 
correlation being stronger among atopics. In the latter study, subjects were steroid-naive, 
whereas in the former study, the majority were on steroid treatment. Most studies have 
included only nonsmokers, but some studies also ex-smokers (Warke et al. 2002, Langley 
et al. 2003, Porsbjerg et al. 2007), and not always is the subjects’ smoking status defined 
(Crimi et al. 1998, Ichinose et al. 2000, Berkman et al. 2005). This adds to the number of 
factors possibly influencing the correlation results, as smoking history (current or former) 
may influence the cellular composition of the airway inflammation, and the likelihood of 
permanent changes in the airways increases with increasing length of smoking history.  
In asthma patients, bronchial responsiveness to indirect stimuli seems to be more 
closely associated with airway inflammation than is responsiveness to direct stimuli. A 
study comprising 120 atopic asthmatics found eosinophilic inflammation to be more 
closely associated with BHR to AMP than with BHR to methacholine. Percentage of 
sputum eosinophils was found to explain 25% of the variance in BHR to AMP, but it was 
not a significant independent predictor of BHR to methacholine (van den Berge et al. 
2001). Berkman and co-workers (2005) studied 85 subjects with respiratory symptoms 
suggesting asthma but with no evidence of bronchial obstruction in spirometry. In this 
population with atopic and smoking status undefined, FENO correlated significantly with 
exercise, AMP, and methacholine challenges, AMP giving the best correlation, followed 
by exercise. Including only those 45 subjects in whom diagnosis of asthma was verified, a 
significant correlation emerged only between FENO and exercise challenge. Similarly, in 
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a study comprising 21 asthmatics, most of whom were atopics, sputum eosinophils 
correlated significantly with EIB but not with BHR to methacholine (Yoshikawa et al. 
1998). 
2.4 Asthma 
2.4.1 Overview 
During the last 10 years, the number of patients suffering from asthma has doubled 
(Kupczyk et al. 2010), the prevalence in Europe being highest in the UK, 10 to 13% 
(European Lung White Book 2003). In Finland, the FinEsS studies have reported a 6.6% 
prevalence of physician-diagnosed asthma in the Helsinki area (Pallasaho et al. 1999) and 
similarly a 6.4% prevalence in northern Finland (Kotaniemi et al. 2001). The genetic 
predisposition to develop asthma is well recognized and involves especially genes related 
to allergy and to certain cytokines or inflammatory mediators involved in asthma. 
Environmental factors, such as changing patterns of microbial exposure, and exposure to 
allergens and to environmental pollutants, are likely to interact with the genetic 
predisposing factors. Factors responsible for the increased incidence are not fully 
understood, but environmental and lifestyle changes play a major role (Kupczyk et al. 
2010).  
Global Initiative for Asthma (GINA) guidelines define asthma as “a chronic 
inflammatory disorder of the airways in which many cells and cellular elements play a 
role. The chronic inflammation is associated with airway hyperresponsiveness that leads to 
recurrent episodes of wheezing, breathlessness, chest tightness and coughing. These 
episodes are usually associated with variable airflow obstruction that is often reversible 
either spontaneously or with treatment”. Diagnosis of asthma is based on the detection of 
reversible obstruction either in spirometry or in serial PEF measurements in conjunction 
with typical symptoms. For establishing an asthma diagnosis, the Finnish national asthma 
guidelines require improvement of >12% (and > 200 ml) in FEV1 and/or in FVC, or 
repeated improvement of >15% (> 60 l/min) in PEF in response to bronchodilator, or 
repeated diurnal PEF variation of > 20% (Haahtela et al. 2006). In addition, the guidelines 
consider PD15FEV1 < 0.4 mg of histamine or PD20FEV1 < 0.6 mg of methacholine 
specific for asthma in adults. Diagnosis can also be established by detecting improvement 
of > 15% (and > 200 ml) in FEV1 or of > 20% in PEF values during steroid treatment 
(Haahtela et al. 2006). Biopsy studies have shown airway inflammation to be present even 
at a clinically early stage of asthma (Laitinen et al. 1993, Jeffery 1996), and several studies 
have demonstrated early intervention with ICS to provide significant long-term benefits 
such as prevention of irreversible changes in the airway and reduction in occurrence of 
severe asthma exacerbations and decline in lung function in adult patients (Haahtela et al. 
1994, Pauwels et al. 2003, O’Byrne et al. 2009, Haahtela et al. 2009). 
 
 
 
 
28
2.4.2 Asthma, airway inflammation, and FENO 
Although asthmatic airway inflammation is often referred to as eosinophilic inflammation, 
it is much more complex than simple eosinophilic inflammation alone. It is characterized 
by activated mast cells, infiltration of eosinophils, and increased number of T-helper 2 
(Th2) lymphocytes, accompanied by increased expression of multiple inflammatory genes, 
regulated by proinflammatory transcription factors (Djukanovic et al. 1990, Laitinen et al. 
1993, Bousquet et al. 2000). Eosinophils play a central deleterious role by release of 
proinflammatory mediators and cytokines resulting in vascular leakage, in 
hyperproduction of mucus, in smooth muscle constriction, and in epithelial shedding. 
They are also involved in the regulation of airway inflammation and initiate the 
remodeling process by release of cytokines and growth factors (Bousquet et al. 2000). 
Mast cells are critical “trigger cells” in eliciting acute bronchoconstriction, mucus 
secretion, and edema by the release of histamine and other vasoactive mediators. Mast 
cells also release proteases, and mast cell products activate fibroblasts, thus potentially 
playing a role in airway remodeling (Bousquet et al. 2000). Infiltration of airway smooth 
muscle by mast cells has been detectable in asthma but not in eosinophilic bronchitis, 
suggesting their role in bronchial hyperresponsiveness (Brightling et al. 2002). In addition 
to the increased cell numbers in asthmatic airway inflammation, an essential feature is the 
cell activation which results in production and release of cytokines such as interleukin (IL) 
4, IL-5, and IL-13, which induce the immunoglobulin (Ig) E response and promote 
eosinophil chemotaxis. An increased number of neutrophils is reported in severe asthma 
(Jatakanon et al. 1999b), but a subgroup with predominantly neutrophilic airway 
inflammation has been detected also among patients with mild to moderate asthma (Green 
et al. 2002b). The epithelium in asthma is partially shed, and goblet cells appear in greater 
numbers than in healthy subjects. Epithelial cells may be important in regulating airway 
remodeling and fibrosis because they release fibrogenic growth factors (Bousquet et al. 
2000).   
Asthma has been divided into two subtypes: atopic (or allergic or extrinsic) and 
nonatopic (or nonallergic or intrinsic) asthma, since 1947, when Rackeman introduced the 
concepts of extrinsic and intrinsic asthma based on differences in the clinical phenotype of 
the disease (Rackeman 1947). Nonatopic asthma in adults is characterized by female 
dominance, later onset, more severe clinical course, and higher prevalence of nasal 
polyposis than in atopic asthma (Romanet-Manet et al. 2002). Even though atopic and 
nonatopic asthma share common immunopathological features (Humbert et al. 1999), 
some differences have been detected in their cellular pattern of inflammation (Amin et al. 
2000, 2005) and in their cytokine production (Amin et al. 2000, Bettiol et al. 2000). 
Airway inflammation with increased numbers of eosinophils and mast cells is a feature of 
both atopic and nonatopic asthma, but biopsy studies by Amin and co-workers have found 
infiltration of eosinophils in the airway mucosa to be more prominent in atopic than in 
nonatopic asthma (Amin et al. 2000), and mast cell numbers and extracellular deposition 
of mast cell products in smooth muscle compartment to be higher in atopic than in 
nonatopic asthma (Amin et al. 2005). Furthermore, increased number of neutrophils and 
higher expression of IL-8 have both been detectable in nonatopic asthma (Amin et al. 
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2000). In contrast, biopsy studies by Karjalainen and co-workers (2003) found no 
difference in inflammatory cell profile between newly diagnosed atopic and nonatopic 
asthma. Both studies, however, found a significantly thicker basement membrane tenascin 
layer in atopic than in nonatopic asthma (Amin et al. 2000, Karjalainen et al. 2003). 
Whether this difference is directly related to the atopic constitution or possibly to a 
secondary factor such as duration of disease is still unclear. However, differences have 
been detectable in cytokine production between atopic and nonatopic asthma. Higher 
numbers of IL-4- and IL-5-positive cells have appeared in atopic asthma (Amin et al. 
2000), and atopic but not nonatopic asthma has been characterized by increased IL-4 
production, which correlates with eosinophilic inflammation (Bettiol et al. 2000). In atopic 
asthma, spontaneous production of IFN-γ, which suppresses IgE production, has been 
found to be impaired (Bettiol et al. 2000). 
The first observation of increased FENO in atopic asthmatics was in 1993 (Alving et 
al. 1993). Since then, numerous studies have confirmed that steroid-naive atopic asthma is 
associated with increased FENO (Taylor et al. 2006), whereas studies on nonatopic asthma 
have reported conflicting results, with some reporting increased FENO (Zietkowski et al. 
2006, Malinovschi et al. 2009), with others reporting no difference from levels in healthy 
controls (Lúdvíksdóttir et al. 1999, Graziou et al. 1999, Olin et al. 2004). A study by 
Ekroos and co-workers (2009) found higher FENO in nonatopic steroid-naive asthmatics 
than in healthy controls. Interestingly, FENO in low-sensitized atopic asthmatics (defined 
as total skin prick test wheal sum 3-10 mm) was similar to FENO in nonatopic asthmatics, 
whereas FENO among high-sensitized atopic asthmatics (defined as total skin prick test 
wheal sum > 10 mm) was significantly higher (Ekroos et al. 2009). When assessing 
patients with symptoms suggesting asthma, high FENO values have been found useful 
both in atopic and nonatopic asthma (Malmberg et al. 2005). 
Since asthma is a heterogeneous disease, detailed phenotyping of asthma has been 
suggested instead of the current dichotomy; this might allow the successful targeting of 
therapies to those patients most likely to gain benefit (Wenzel 2006, Bradding & Green 
2010). Significant differences in airway hyperresponsiveness and in FENO levels have 
occurred between some suggested subtypes (Porsbjerg et al. 2009); thus, BHR and FENO 
measurements could help in phenotyping these patients. 
2.4.3 FENO and asthma diagnosis 
Diagnosis of asthma is based on demonstrating variable airflow obstruction, whereas 
assessment of airway inflammation, the central feature of asthma, is not included in the 
diagnostic work-up. Presence of airflow obstruction may be intermittent, or particularly in 
mild asthma, it may not be present at the time of measurement, thus leaving the diagnosis 
open. Smith and co-workers (2004) compared FENO measurements with conventional 
tests (PEF measurements, spirometry) for diagnosis of asthma in 47 consecutive patients 
with symptoms suggesting asthma, and found sensitivities for conventional tests (0-47%) 
to be lower than for FENO (88%) or sputum eosinophils (86%), when in addition to 
symptoms, BHR or bronchodilatation response or both were the diagnostic criteria. A 
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study by Dupont and co-workers (2003) including 240 nonsmoking steroid-naive patients 
with respiratory symptoms reported FENO to be highly predictive of asthma, with 
sensitivity of 85% and specificity of 90%. A large population survey concluded that the 
combination of elevated FENO and increased BHR is a very specific finding for atopic 
asthma (Henriksen et al. 2000).  
Assessment of airway inflammation in clinical practice would prove useful, as patients 
with asthma-like symptoms and signs of airway inflammation but with normal lung 
function are reported to benefit from steroid treatment (Rytilä et al. 2000). The rationale 
for measuring FENO is its ability to predict response to steroid treatment in patients with 
respiratory symptoms irrespective of exact diagnosis (Taylor et al. 2006). Moreover, 
importantly, the predictive value of a normal FENO for the absence of eosinophilic airway 
inflammation has been high, permitting steroid-unresponsive symptoms to be 
differentiated from those which are steroid responsive (Shaw et al. 2007). 
Chronic cough is a common nonspecific symptom often present also in asthma. 
Frequently in mild asthma, no signs of reversible airway obstruction appear. Several 
studies have found FENO measurement useful in the assessment of chronic cough in 
predicting response to ICS. Chatkin and co-workers (1999) reported a positive predictive 
value of 60% and a negative predictive value of 93% with FENO ≥ 30 ppb serving as a 
cut-off value, and with FENO measured at a flow rate of 45 ml/s. In a retrospective study 
of 64 patients with chronic cough, 88% of subjects with elevated FENO showed a 
significant improvement in their cough following ICS treatment, whereas only 9% of 
subjects with normal FENO responded to ICS (Hahn et al. 2007). A cut-off of 38 ppb 
(flow rate 50 ml/s) best differentiated between ICS responders and nonresponders among 
patients with cough (Sato et al. 2008). A recent large study also supported the view that 
normal FENO predicts low likelihood of response to ICS (Oh et al. 2008). Furthermore, a 
recent study conducted in primary health care found FENO measurement to improve 
diagnostic confidence in assessment of nonspecific respiratory symptoms, with both 
normal and high FENO values having clinical significance (Hewitt et al. 2008).  
2.4.4 FENO and asthma management 
Asthma control is usually monitored by frequency of symptoms, serial measurements of 
PEF, or spirometry. Measures of lung function correlate poorly with the degree of airway 
inflammation, and perception of symptoms varies considerably, making these tools 
inadequate for assessment of the sufficient dose of ICS for controlling airway 
inflammation (Taylor et al. 2006). Furthermore, in mild cases, lung function can be 
normal even before initiation of ICS, leaving no room for improvement. Management 
strategies which aim at minimizing eosinophilic airway inflammation by monitoring 
sputum eosinophilia have shown substantial reduction in frequency of severe asthma 
exacerbations during one- or two-year study periods without increasing the total 
corticosteroid dose (Green et al. 2002a, Jayaram et al. 2006).  
With steroid treatment, FENO levels rapidly decrease (Kharitonov et al. 1996a, 1996b, 
2002, Jatakanon et al. 1999a), and they increase again along with deterioration of asthma 
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control (Jones et al. 2001). The results of the first study applying FENO-based asthma 
management in comparison with conventional management in a study population of 94 
asthmatics appeared in 2005 (Smith et al. 2005). The FENO-based algorithm resulted in 
reduction in ICS dose without compromising asthma control, and the exacerbation rate 
was slightly although not significantly lower than in the conventionally managed group. 
The study design, however, was criticized for favoring reduction in ICS dose in the FENO 
group. Conflicting results were reported by Szefler and co-workers (2008), who found no 
benefit from FENO-based management compared to conventional management in terms of 
ICS dose, exacerbation rate, pulmonary function or symptoms among 12- to 20-year old 
mild asthmatics despite the fact that the dose of ICS was higher in the FENO group at the 
end of the study. In only some subgroups, such as in atopic or obese subjects, did FENO-
guided management improve asthma control (Szefler et al. 2008). The study applied a 
FENO threshold of < 20 ppb to identify good control, this level being lower than the 
suggested reference range (Olin et al. 2007), and the study design allowed only an 
increase, not a decrease in ICS dose based on FENO levels. A third study with a similar 
setting including 118 adults (20-81 yrs) with a study period of 12 months, reported a lower 
final dose of ICS in the group with FENO-based management, but no significant 
difference in exacerbation frequency (Shaw et al. 2007).  
Exacerbation frequency predicts lung function decline. Clinical markers identifying 
patients at risk for exacerbation could allow modification of asthma medication in order to 
prevent exacerbations. The decrease in FENO during steroid treatment for asthma 
precedes the improvement of symptoms, of FEV1, and of sputum eosinophilia (Jatakanon 
et al. 1999a), and similarly, an increase in FENO may be detectable with deterioration of 
asthma control before detection of significant changes in PEF variability or spirometry. A 
study by Jones and co-workers (2001) reported both single measurements and an increase 
of > 60% over baseline in FENO (measured at a flow rate of 250 ml/s) having positive 
predictive values ranging from 80 to 90% for the prediction and diagnosis of loss of 
asthma control. Gelb and co-workers (2006) measured FENO at a flow rate of 100 ml/s 
and found combined baseline FENO ≥ 28 ppb and FEV1 ≤ 76% of predicted value to 
identify asthmatics with 85% probability of future exacerbation. FENO measurement in 
subjects with difficult-to-treat asthma could help in identifying subjects who may benefit 
from an increased steroid dose. In a study by Pérez de Llano and co-workers (2009), 
subjects with suboptimal asthma control with maximal fluticasone-salmeterol combination 
were treated with a course of oral steroids. A FENO value ≥ 30 ppb demonstrated 
sensitivity of 87.5% and specificity of 90.6% for identification of responders to the course 
of oral steroids. 
How best to interpret individual FENO measurements during treatment of asthma is 
still unclear. A large study on unselected asthmatics reported that changes in FENO values 
rather than absolute cut-off points may be meaningful for longitudinal assessment of 
asthma control (Michils et al. 2008). A 40% reduction in FENO proved to be a reliable 
predictor of asthma control optimization, and an increase < 30% to be helpful in excluding 
the occurrence of any significant deterioration. A recent study by Smith and co-workers 
(2009) demonstrated in those asthmatics whose phenotype is characterized by elevated 
FENO levels when symptomatic, that “personal best” FENO levels were lower with oral 
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than with inhaled steroid treatment. FENO levels after a course of oral steroids 
approximated the predicted values from the reference equations by Olin and co-workers 
(2007) and to a lesser extent approximated those suggested by Travers and co-workers 
(2007). However, targeting reference values may not be justified, as optimized doses of 
ICS have resulted in well-controlled asthma even when FENO levels exceeded those  
predicted. The study suggested that, rather than predicted values, the absolute values or the 
magnitude of changes in FENO in relation to personal best obtained when asthma is well 
controlled, is more likely to be informative (Smith et al. 2009).   
A Cochrane Database review in 2009 concluded that tailoring the dose of ICS based on 
FENO has been beneficial in reducing the final (but not overall) daily ICS doses in adults, 
but this approach cannot be routinely recommended for clinical practice at this stage 
(Petsky et al. 2009). It is clear that routine measurements would not be useful, as FENO is 
not elevated in all asthmatics, elevated FENO does not equal eosinophilic inflammation, 
and inflammation in asthma is not always eosinophilic. Further studies are needed to 
identify the subgroups that benefit from FENO-based management of asthma and to 
develop a correct algorithm for this purpose.  
 
2.5 COPD 
2.5.1 Overview 
Chronic obstructive lung disease (COPD) causes a major health burden worldwide, 
currently being the world’s fourth most common cause of death (WHO 2008a), and 
predicted to rise to third place by the year 2020, just after ischemic heart disease and 
cerebrovascular disease (Murray & Lopez 1997). The pulmonary pathology of COPD can 
involve changes in the airway mucosa (increased number of goblet cells responsible for 
increased mucus production, reduced number of ciliated cells), obstruction in the small 
airways caused by inflammation and fibrosis, and structural changes in lung parenchyma 
(destruction of alveolar walls, abnormal enlargement of airspaces, loss of lung elasticity) 
adding to airway obstruction (Rabe et al. 2007). Systemic inflammation may be present, 
related to an accelerated decline in lung function and systemic manifestations of the 
disease (Barnes & Celli 2009).  
Despite the multicomponent nature of the disease, diagnosis of COPD is usually based 
on detection of airflow obstruction in spirometry, because the pulmonary components of 
COPD are usually reflected in airflow indices detected in spirometry. Prevalence estimates 
differ, depending largely on the diagnostic definition of the disease and the population 
studied. The prevalence of physician-diagnosed COPD is much lower than suggested by 
population-based spirometric surveys, indicating that underdiagnosis of COPD is common 
(Mannino et al. 2000, Bednarek et al. 2008). The most widely used GOLD guidelines 
recommend a post-bronchodilator FEV1-to-FVC ratio < 0.7 to define airflow limitation, 
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and the grading of disease severity by FEV1 in relation to the predicted value (Global 
Initiative for Chronic Obstructive Lund Disease). The global BOLD study, applying these 
criteria, reported 10% prevalence of GOLD stage II or higher (FEV1 < 80% of predicted) 
(Buist et al. 2007). Although easy to use, this fixed cut-off ratio has been widely criticized, 
since it has been found to result in significant overestimation of COPD in older 
individuals and underestimation in younger adults (Pellegrino et al. 2008, Vollmer et al. 
2009, Miller et al. 2009). Use of the lower limit of normal (LNN) both in FEV1-to-FVC 
ratio and in FEV1 to diagnose COPD, apparently has the least bias (Vollmer et al. 2009), 
and its use is recommended in the current ATS/ERS guidelines on lung function testing 
(Pellegrino et al. 2005). For grading of disease severity, the use of FEV1 alone does not 
adequately reflect all systemic manifestations of COPD. Multidimensional tools such as 
the BODE index (combination of body mass index, degree of obstruction, dyspnea score, 
and exercise capacity as measured by a 6-min walking test) may be useful to capture the 
multidimensional nature of COPD (Celli et al. 2004, Barnes & Celli 2009).  
The direct causal relationship between tobacco smoke and COPD is well established 
(US Public Health Service 1984), and COPD prevalence corresponds directly to the 
smoking habits of the population with a 20-year latency. The frequent statement that 15 to 
20% of smokers develop airway obstruction has proven to be an underestimate, as recent 
studies have shown that up to 50% of smokers develop COPD (Lundbäck et al. 2003, 
Rennard & Vestbo 2006, Kotaniemi et al. 2005, Mannino & Buist 2007). The only 
recognized genetic risk factor, severe α1-antitrypsin deficiency, concerns only 1 to 3% of 
patients with COPD (Mannino & Buist 2007). Occupational exposure to vapors, gases, 
fumes, or dusts raises the risk for COPD, but joint exposure to both smoking and 
occupational factors has a synergistic effect with markedly increased risk compared to 
exposure to occupational factors alone (Jaakkola 2009). Globally, also exposure to 
biomass fuels, especially to cooking gases in poorly ventilated homes, has been assessed 
to be an important risk factor for COPD (Mannino & Buist 2007). 
In general, airway pathology in COPD is unresponsive to steroid treatment, but COPD 
is a heterogeneous disease, with some subgroups of patients likely to benefit from steroid 
treatment, and some patients finding it even detrimental (Yang et al. 2007, Drummond et 
al. 2008). Identification of the correct subjects for steroid treatment is not simple: 
differential diagnosis between asthma and COPD is not always clear, as the clinical course 
of asthma sometimes leads to fixed airway obstruction, whereas partial reversibility may 
be present in COPD, and these diseases are also reported often to co-exist (Marsh et al. 
2008). Treatment should also aim at reduction of exacerbation frequency, since 
exacerbations are known to lead to faster FEV1 decline (Donaldson et al. 2002). 
Currently, regular treatment with ICS is recommended for COPD patients with FEV1       
< 50% of predicted and repeated exacerbations (Rabe et al. 2007). 
2.5.2 COPD and airway inflammation 
Airway inflammation in COPD is characterized by an increase in macrophages, 
neutrophils, and cytotoxic (CD8+) T-lymphocytes. This pattern is also seen in smokers 
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with normal lung function, but in COPD the inflammation is amplified. Alveolar 
macrophages, activated by cigarette smoke and other inhaled irritants, release increased 
amounts of proteinases, inflammatory mediators, neutrophil chemotactic factors, and 
reactive oxygen species (Barnes et al. 2006a, Bourdin et al. 2009). Furthermore, alveolar 
macrophages of COPD patients show a marked reduction in the activity of histone 
deacetylase (HDAC), an inhibitor of cytokine production. This impaired function at least 
partly explains the steroid resistance in COPD, as steroids exert their anti-inflammatory 
properties via activation of HDAC (Barnes et al. 2006a, Barnes 2006b). Increased 
numbers of neutrophils are present prominently in the airway lumen, and also in the 
airway smooth muscle (Rutgers et al. 2000, Baraldo et al. 2004). Their numbers correlate 
with pack years and number of cigarettes smoked per day as well as with the COPD 
severity (Chalmers et al. 2001); with worsening disease severity, tissue neutrophilia 
increases (Barnes et al. 2006a). Neutrophils are the major providers of proteinases, which 
may contribute to the alveolar destruction and act as potent stimulants for mucus 
production. Levels of IL-8, a potent neutrophil chemoattractant, are higher in COPD than 
in healthy smokers, and correlate negatively with disease severity, and IL-8 is further 
increased during exacerbations (Barnes et al. 2006a). An increase in total elastase activity 
and a decrease in antielastase activity are reported in COPD patients compared to levels in 
healthy smokers (Barnes et al. 2006a). CD8+ T-lymphocytes are higher in the airways of 
smokers with COPD than in healthy smokers. They may cause cytolysis and apoptosis of 
the alveolar epithelial cells and have been found to correlate negatively with degree of 
airflow limitation (O’Shaughnessy et al. 1997, Saetta et al. 1998). Eosinophils are present 
in the airways of some COPD patients, and during exacerbations their numbers may 
increase considerably (Saetta et al. 1994).  
Sputum eosinophilia in COPD patients appears to predict a larger bronchodilator 
response and improvement with corticosteroids (Papi et al. 2000). A course of oral 
steroids has resulted in an improvement in FEV1 also in those patients with fixed airway 
obstruction who have increased eosinophil counts in peripheral blood or in sputum 
(Brightling et al. 2000, Fabbri et al. 2003). Increased sputum eosinophil count in one study 
was related to a small but significant improvement in FEV1 following 4-week treatment 
with inhaled mometasone in subjects with fixed airway obstruction, even though no 
reduction in symptoms or in sputum eosinophil count was detectable (Brightling et al. 
2005). Another study with a similar setting found improvement both in FEV1 and in 
symptoms as well as normalization of sputum eosinophils following inhaled budesonide 
treatment in COPD patients with increased sputum eosinophilia at baseline (Leigh et al. 
2006). A recent study including 82 COPD patients showed that a management strategy 
aimed at minimizing sputum eosinophilia resulted in a significant reduction in severe 
COPD exacerbations compared to that in conventional management strategy, with no 
overall increase in steroid use (Siva et al. 2007).    
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2.5.3 COPD and FENO 
FENO in stable COPD patients has been reported to range from low (Clini et al. 1998) to 
elevated (Corradi et al. 1999, Ansarin et al. 2001, Zietkowski et al. 2005, Liu et al. 2007, 
Beg et al. 2009) when compared to FENO in healthy subjects, with several studies 
reporting no difference between these groups (Kanazawa et al. 1998, Rutgers et al. 1999, 
Delen et al. 2000, Ziora et al. 2007). Increased FENO has been reported during COPD 
exacerbations (Agusti et al. 1999). This variability may in part be explained by the 
heterogeneous nature of the disease, with multiple factors influencing FENO. At the 
alveolar level, NO rapidly combines with reduced hemoglobin (400 times faster than CO) 
and is therefore scavenged by pulmonary capillary blood. In the presence of an altered 
ventilation-perfusion mismatch in COPD, this scavenging will take place less efficiently. 
Destruction of alveolar epithelial cells in more severe COPD may influence NO-
production in the airways, and the development of cor pulmonale in severe COPD may 
reduce FENO, presumably as a reflection of endothelial injury. Furthermore, smoking 
(current or former) influences the composition of the airway inflammation and thus FENO 
formation. Several studies have included patients receiving steroid treatment, which 
further influences the results. Similarly, studies trying to correlate FENO and the indices 
of COPD severity have provided conflicting results (Clini et al. 1998, Ansarin et al. 2001, 
Bhowmik et al. 2005). Various methodologies and various flow rates for measuring FENO 
have been applied over the years. The conventional technique of FENO measurement 
reflects NO derived mainly from the large airways. Measurement of FENO at different 
flow rates enables one to differentiate airway-derived NO and peripheral NO derived from 
alveoli and probably from the small airways (Brindicci et al. 2005, Barnes et al. 2006a). 
An increase in peripheral NO is related to COPD severity and as it is insensitive to 
smoking, it thus may prove a useful noninvasive biomarker of COPD inflammation 
(Barnes et al. 2006a). Peripheral NO is, however, insensitive to corticosteroid treatment, 
and thus not useful as a marker predicting steroid response (Brindicci et al. 2005, 
Lehtimäki et al. 2010).  
Corresponding to the positive results regarding the influence of steroid treatment in 
COPD patients with sputum eosinophilia, several studies have reported similar results 
when assessing the presence of airway inflammation by measuring FENO. A study by 
Ferreira and co-workers (2001) was the first to report a significant decrease in FENO in 
ex-smokers with COPD during a 2-week ICS treatment as well as a significant negative 
correlation between the change in FENO and the change in FEV1. Zietkowski and co-
workers (2005) found a significant decrease in FENO after 2 months on ICS, with the 
initial level of FENO correlating with the decrease in FENO and with the increase in 
FEV1 after ICS therapy. Kunisaki and co-workers (2008) found significantly higher 
baseline FENO in those ex-smokers with severe COPD who showed significant 
improvement in FEV1 (≥ 200 ml) during 4-week treatment with ICS. A study measuring 
bronchial and alveolar NO in 40 COPD patients found higher baseline bronchial NO to be 
associated with improvement in airway obstruction and symptoms in response to 4-week 
treatment with ICS. This treatment reduced bronchial NO flux but not alveolar NO 
concentration (Lehtimäki et al. 2010). As the complexity of COPD is not fully reflected by 
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measuring only FEV1, it is important that studies examining the influence of steroid 
treatment assess also its impact on symptoms and exercise capacity. 
2.6 Smoking 
2.6.1 Overview 
Smoking is a risk factor for six of the eight leading causes of death, and the single most 
preventable cause of death in the world. Tobacco kills up to half its regular users, on 
average 15 years prematurely, causing today 1 in 10 deaths among adults worldwide, 5.4 
million deaths per year (WHO 2008b). Despite the decline in the proportion of smokers in 
many developed countries, the tobacco epidemic is still increasing in the developing 
world. In developed countries about 35% of men smoke, compared with almost 50% of 
men in developing countries (Shafey et al. 2003).  In 2008, in Finland, 24% of men and 
18% of women (aged 15-64) were current smokers, and 21% of men and 16% of women 
former smokers (Helakorpi et al. 2009). 
The adverse effects of smoking on respiratory health start already in prenatal life. 
Exposure to tobacco smoke especially during pregnancy and in early childhood 
permanently impairs lung function, causes a greater frequency of respiratory tract 
infections and raises the risk for asthma (Svanes et al. 2004, Pietinalho et al. 2009). 
Results from epidemiological and family studies indicate that genes predisposing to 
asthma interact with environmental tobacco smoke exposure early in life (Hylkema et al. 
2007). In infants and young children, the proinflammatory effects of tobacco smoke may 
be reflected in increased NO levels (Franklin et al. 2006). Exposure to tobacco smoke 
(active and passive smoking) is associated with slowed lung function growth, and early 
onset of lung function decline in adolescents, with girls possibly more vulnerable to this 
effect (Gold et al. 1996). Smoking is associated with increased bronchial 
hyperresponsiveness (Willemse et al. 2004a), and several studies have found an increased 
risk for asthma in smokers, although contradictory results have also appeared (Thomson et 
al. 2004). Smokers with asthma have worse asthma control independent of FEV1, an 
accelerated decline in lung function, and an increased mortality rate (Thomson et al. 2004, 
Hylkema et al. 2007, Chaudhuri et al. 2008), and their response to corticosteroids is 
impaired (Pedersen et al. 1996, Chalmers et al. 2002, Thomson & Spears  2005). In 
addition, passive exposure to tobacco smoke has been reported to increase asthma risk 
(Jaakkola et al. 2002) and to worsen asthma control (Pietinalho et al. 2009). COPD has 
been reported to develop in up to 50% of those who smoke till their later middle age, with 
the risk increasing the younger the smoking begun  (Lundbäck et al. 2003, Kotaniemi et 
al. 2005). COPD patients who continue to smoke have a faster decline in lung function, 
more exacerbations, more symptoms, and increased mortality compared to those who quit 
smoking (Anthonisen et al. 1994, Willemse et al. 2004a, Godtfredsen et al. 2008). 
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2.6.2 Smoking and airway inflammation 
Smoking has the capacity to damage the airways in several ways: direct toxic damage to 
the epithelium, oxidative damage, recruitment of inflammatory cells, and increased 
epithelial permeability. Cigarette smoke contains an abundance of oxygen-based free 
radicals, peroxides, and peroxynitrite, placing a significant oxidant burden on the lungs. 
Oxidative stress induces chemotaxis, potent leukocyte adhesion, and initiation of 
inflammation. Furthermore, oxidants change the proteinase-antiproteinase balance, 
resulting in reduction in the antiproteinase shield and an increase in proteinolysis 
(Bourdain et al. 2009, Pietinalho et al. 2009). 
Chronic and repeated exposure to cigarette smoke stimulates the activation of 
macrophages and neutrophils. Activated macrophages secrete cytokines such as IL-8, 
inducing neutrophil chemotaxis.  Increased numbers of neutrophils are present in the 
induced sputum of healthy and asthmatic smokers (Chalmers et al. 2001, Rytilä et al. 
2006), with a significant positive correlation between sputum neutrophils and smoking 
history (Chalmers et al. 2001). Bronchial biopsies from asymptomatic smokers show an 
excess of several inflammatory cell types (neutrophils, eosinophils, mast cells, and 
macrophages) in the bronchial mucosa, having a clear relationship with the impaired 
epithelial integrity (Amin et al. 2003). Increased numbers of mast cells have been found in 
all compartments, structural changes correlating with mast cell numbers, especially in the 
smooth muscle (Ekberg-Jansson et al. 2005). Increased thickness of the basement 
membrane has been reported to relate strongly to the presence of eosinophils and mast 
cells, suggesting a role for these cells in the remodeling of the airways that occurs in 
asymptomatic smokers (Amin et al. 2003). Chronic exposure to cigarette smoke can 
disturb epithelial regeneration, leading to excessive epithelial proliferation (Lee et al. 
2001). 
Smoking is known to alter the composition of asthmatic airway inflammation. 
Inflammation in the asthmatic smoker is shifted from an eosinophil-dominated towards a 
neutrophil-dominated pattern. Increased numbers of eosinophils do occur, but their 
proportion in smokers is lower (Chalmers et al. 2001, Broekma et al. 2009). This may in 
part result from increased apoptosis of activated eosinophils caused by exogenous NO in 
cigarette smoke (Zhang et al. 2003). Induced sputum both in healthy smokers (Rytilä 
2006) and in steroid-naive asthmatic smokers (Chalmers et al. 2001) contains higher 
numbers of neutrophils than in their nonsmoking counterparts. Increased expression of 
intraepithelial IL-8 has been detectable in bronchial biopsies of asthmatic smokers 
compared to that in asthmatic nonsmokers (St-Laurent et al. 2008), and its release is 
augmented by exposure to cigarette smoke (Mio et al. 1997). IL-8 correlates positively 
with number of neutrophils in sputum, and increases significantly with increasing pack-
years (Chalmers et al. 2001). Similarly, the increased epithelial cell proliferation detected 
in asthmatic smokers has been reported to correlate with higher number of pack-years 
(Broekma et al. 2009). Higher mast cell numbers also appears in asthmatic smokers than 
in nonsmokers (Broekma et al. 2009). Whether the influence of smoking on asthmatic 
airway inflammation differs between atopic and nonatopic asthma, is, however, unknown.  
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Smoking cessation occurring sufficiently early can lead to reversal of the 
inflammation, although normalization may take several months (Willemse et al. 2004a). 
However, once COPD is established, inflammation may continue to persist, although 
some improvement may take place (Rutgers et al. 2000, Willemse et al. 2004a). Despite 
the persisting inflammation and irreversible damage to the lung parenchyma, smoking 
cessation slows the progression of COPD and clearly reduces the accelerated rate of 
decline in FEV1 (Fletcher & Peto 1977, Anthonisen et al. 1994, 2002). Smokers with 
airflow obstruction benefit from quitting despite previous heavy smoking, advanced age, 
poor baseline lung function, or airway hyperresponsiveness (Scanlon et al. 2000).  
In asthma, epithelial changes and the increase in neutrophil and mast cell numbers are 
likely to be reversed with smoking cessation (Broekma et al. 2009), and steroid 
responsiveness may at least be partially restored (Hylkema et al. 2007). Cigarette smoke 
may have direct effects on airway smooth muscle responsiveness, and intensity of 
smoking, assessed as pack years, has been reported to relate to BHR severity (Piccillo et 
al. 2008). Smoking cessation has been reported to improve BHR to indirect stimulus 
earlier and to a greater extent than it improves BHR to direct stimuli, but whether the 
degree of BHR after smoking cessation reverts to normal levels, is controversial 
(Willemse et al. 2004a, Willemse et al. 2004b, Piccillo et al. 2008). Smoking cessation, 
however, may prevent future deterioration of BHR (Wise et al. 2003). 
2.6.3 Smoking and FENO 
In both healthy and steroid-naive asthmatic subjects compared to their nonsmoking 
counterparts, active smoking is associated with reduced FENO (Persson et al. 1994, 
Kharitonov et al. 1995a, Verleden et al. 1999, Horváth et al. 2004, McSharry et al. 2005, 
Rytilä et al. 2006). Exposure to environmental tobacco smoke may also reduce FENO 
(Yates et al. 2001b, Laoudi et al. 2009), although increased FENO concentrations have 
been reported in infants (Franklin et al. 2006). A negative correlation between FENO and 
the amount smoked has appeared in several studies (Persson et al. 1994, Kharitonov et al. 
1995a, Corradi et al. 1999), whereas some have found no such correlation (Verleden et al. 
1999, Horváth et al. 2004).  
Smoking may reduce FENO by several mechanisms. Decreased iNOS activity caused 
by negative feedback from high concentrations of NO in cigarette smoke has been 
proposed to account for the decrease in FENO after acute inhalation of cigarette smoke. 
Kharitonov and co-workers (1995a) showed, however, that inhalation of NO itself did not 
result in any decrease in FENO levels. This transient decrease in FENO probably results 
from a reaction between NO and the high concentration of reactive oxygen species in 
cigarette smoke, with NO from the airways being captured by peroxynitrite formation 
(Horváth et al. 2004). Chronically reduced FENO levels in smokers may be due to smoke-
induced toxic damage to NO-producing epithelial cells. Exposure to cigarette smoke 
extract has been reported to inhibit cytokine-induced production of NO by epithelial cells 
and mast cells, and to inhibit the expression of NO synthase in these cells (Hoyt et al. 
2003, Wei et al. 2005). Bergeron and co-workers (2007) reported increased arginase 
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expression in bronchial biopsies from steroid-naive smoking asthmatics. Because NO is 
synthesized from arginine, increased arginase activity leads to less substrate for NOS and 
thus to a decrease in NO formation. In asthmatic smokers, inhalation of nebulised L:-
arginine can reverse the cigarette-induced reduction of FENO (Bruce et al. 2010). A 
significant negative correlation has been reported between FENO and the number of 
neutrophils in induced sputum (Rytilä et al. 2006). Reduced FENO in smokers may be 
related to their increased susceptibility to respiratory infections in smokers, since NO 
production is involved in local host defense and is necessary for normal ciliary beating in 
the airway mucosa (Nathan & Hibbs 1991, Jain et al. 1993).  
Although studies show lower FENO levels in steroid-naive asthmatic smokers than in 
their nonsmoking counterparts and elevated levels compared to healthy smokers, limited 
data are available comparing FENO in steroid-naive asthmatic smokers to FENO in 
healthy nonsmokers. As smoking prevalence among asthmatics is at least at the same level 
as among the general population (Pietinalho et al. 2009) and as reference values are based 
on levels in nonsmokers (Olin et al. 2007), it would be essential to know whether FENO 
in steroid-naive asthmatic smokers differs significantly from FENO in healthy 
nonsmokers in order to evaluate the usefulness of FENO to reflect airway inflammation in 
smokers with respiratory symptoms. Furthermore, whether the influence of smoking on 
FENO between atopic and nonatopic asthmatics differs, is unknown. Horvath and co-
workers (2004) found higher FENO among 22 steroid-naive atopic asthmatic smokers 
than among healthy smokers, but did not report any comparison to healthy nonsmokers. A 
study by Verleden and co-workers (1999) reported higher FENO among 13 steroid-naive 
asthmatic smokers than among healthy smokers, but no difference when compared to 
healthy nonsmokers. That study did not assess subjects’ atopic status. Malinovschi and co-
workers (2009), studying 65 atopic and 33 nonatopic asthmatics, found increased FENO 
in atopic and nonatopic steroid-naive asthmatic never-smokers, whereas no difference 
from non-asthmatics was detectable when current and ex-smokers were included. They 
performed no comparison between atopic and nonatopic smokers, and did not report the 
numbers of smokers, ex-smokers and never-smokers within the groups.    
Although FENO in asthmatic smokers is lower than in asthmatic nonsmokers, this 
does not necessarily reduce its ability to reflect asthma control in smokers, if the 
assessment is based on changes in FENO in repeated measurements rather than on cut-off 
values in single measurements. Michils and co-workers (2009) reported that a FENO 
increase < 50% in smokers with controlled asthma would indicate that asthma remains 
controlled, whereas a FENO reduction of < 20% in smokers with uncontrolled asthma 
would indicate that it remains uncontrolled (Michils et al. 2009).  
After smoking cessation, FENO has been reported to rise gradually within weeks, 
approaching normal values after 4 to 8 weeks (Robbins et al. 1997, Högman et al. 2002). 
Whether normal levels are reached may depend on the status of the airways, because a 
smoking-related decline in FENO may be associated with permanent epithelial damage. 
Similarly, if eosinophilic airway inflammation is present, FENO levels may be elevated 
after smoking cessation, when the FENO-reducing effect of smoking is abolished. 
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3 AIMS OF THE STUDY 
1. To examine the association between FENO and allergic sensitization in healthy 
nonsmoking adults without symptoms or signs of airway disorders and among those with 
respiratory symptoms or diagnosed airway diseases.   
 
2. To evaluate the association of bronchial responsiveness to direct and indirect stimuli 
with nitric oxide-producing airway inflammation, and to compare this relationship among 
atopic and nonatopic patients with various degrees of bronchial hyperresponsiveness and 
airway inflammation. 
 
3. To compare the influence of smoking on FENO in atopic and nonatopic steroid-
naive young adults with current symptomatic asthma, and to compare their FENO levels 
to those in smoking and nonsmoking healthy subjects in order to evaluate the usefulness 
of FENO in assessing airway inflammation in asthmatic smokers. 
 
4. To evaluate the influence of chronic obstruction on the repeatability of FENO by 
assessing short-term variation in FENO in COPD patients and healthy subjects, and to 
assess the clinically significant change in FENO in COPD patients.   
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4 MATERIAL AND METHODS 
In total, 533 subjects participated in the studies. Their clinical characteristics are described 
in Table 2. The local ethics committees approved the studies, and all subjects gave their 
written informed consent. 
4.1 Subjects 
4.1.1 FinEsS study participants (Study I) 
The study population of 248 subjects, aged 26 to 61, originated from among 6 062 
responders to a postal survey performed in 1996 in Helsinki as part of the FinEsS study, a 
large epidemiological investigation on obstructive lung diseases, respiratory symptoms, 
and type I allergy carried out in Finland (Fin), Estonia (Es), and Sweden (S). The original 
study sample of 8 000 20- to 69-year-old inhabitants of Helsinki was obtained from the 
Population Register Centre, randomized by 10-year age cohorts and by gender. Of the       
6 062 responders, 1 200 were randomly selected and invited to clinical studies 
(spirometry, bronchodilatation test, skin prick tests (for those under age 61), and 
structured interview). Half (600) of them were at the same time further randomized also to 
undergo FENO measurement and histamine challenge. Of the 600 invited, 310 (51.7%) 
participated. Technically acceptable FENO measurements were obtainable from 295 of 
310 (95%), with skin prick test data available from 248 of them (84%), forming the actual 
study population. 
From this study population of 248 subjects, a subgroup of healthy asymptomatic 
nonsmoking adults was formed for the main analyses. Subjects were included in this 
group provided they had 1) no significant smoking history (were nonsmokers or ex-
smokers with a history of < 5 pack-years and smoking cessation > 5 years previously), 2) 
no signs of airway obstruction (FEV1/FVC ≥ 88% of predicted (Viljanen et al. 1982), and 
bronchodilator response < 12% increase in FEV1), 3) no significant bronchial 
hyperresponsiveness (PD15FEV1 > 0.4 mg histamine; Sovijärvi et al. 1993), 4) no 
previously diagnosed asthma, chronic bronchitis, or chronic obstructive pulmonary 
disease, chronic or recurrent symptoms of the upper or lower respiratory tracts (cough, 
sputum production, wheezing, shortness of breath, nasal symptoms related to specific 
allergens), and 5) no symptoms of cardiovascular, gastrointestinal, or neurological 
diseases. Furthermore, all subjects had to be free from acute respiratory infections for 3 
weeks prior to the study. The exclusion process is presented in Figure 3. After this 
process, the remaining 73 of the 248 subjects formed the study sample comprising healthy 
asymptomatic nonsmoking subjects. 
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Original random population, 248 subjects
current smokers and ex-smokers
121
bronchodilator response of FEV1 > 12%2
3 PD15FEV1 < 0.4 mg histamine
FEV1/FVC < 88% of predicted6
110
physician-diagnosed asthma or symptoms
suggesting asthma
85
FENO 31.5 (23.2, 39.7)
FENO 20.9  (13.9-42.6)
FENO 15.3 (13.2-45.3)
FENO 17.5 (6.9-70.2)
FENO 16.0 (9.0-95.6)
FENO 17.2 (13.0, 21.5)
FENO 15.5 (2.1-49.8)
FENO 15.8 (2.1-95.6)
FENO 15.7 (2.1-95.6)
FENO 15.5 (2.1-95.6)
FENO 15.5 (2.1-49.8)
FENO 13.9 (2.1-95.6)
FENO 11.7 (2.4-64.5)
20
90
other respiratory symptoms
5
other significant diseases (epilepsy and 
hemiparesis, cardiovascular disease requiring
several medications)
83
2
73 healthy asymptomatic subjects
allergic rhinitis
10
FENO 23.0 (11.6-43.6)
FENO 14.0 (2.1-49.8)
127
 
Figure 3 Exclusion process to select healthy asymptomatic nonsmoking subjects, with median 
and range of FENO (flow rate 50 ml/s) shown for each subgroup. (Reprinted with 
permission from: Rouhos et al. 2008, Clin Respir J, 2:141-148. ©Wiley-Blackwell)   
4.1.2 Army conscripts (Studies II and III) 
Subjects for Studies II and III were enrolled from among army conscripts (age 18-30) 
referred to the Central Military Hospital in Helsinki between 1998 and 2002 because of 
respiratory symptoms (dyspnoea, wheezing, cough, sputum production at rest or related to 
exercise) suggesting asthma. They were consecutively and prospectively enrolled in the 
studies, provided that they had used no inhaled or oral steroids, chromones, or leukotriene 
receptor antagonists during the preceding 2 months, and had no evidence of respiratory 
infections within the preceding 4 weeks. Asthma was the diagnosis when at least one of 
the following criteria were applied: 1) ≥ 15% reversibility of PEF or of FEV1 in 
bronchodilatation test with 0.4 mg of inhaled salbutamol, 2) or ≥ 20% spontaneous daily 
variation in PEF compared to the mean value for the day, 3) or ≥ 10% fall in PEF after 
standardized exercise challenge, 4) or PD15FEV1 ≤ 0.4 mg in the histamine challenge 
(Sovijärvi et al. 1993). Study III included only subjects diagnosed with current 
symptomatic asthma by these criteria, whereas Study II included also symptomatic 
subjects who did not fulfill the criteria of asthma. Study II included only nonsmokers, 
Study III also current smokers. Information on subjects’ smoking history came from an 
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interview with a nurse upon admission to the military hospital. Study III also included 
nine nonsmoking and ten smoking healthy conscripts with no signs, symptoms, or history 
of chronic or recurrent respiratory diseases as a control group.  
4.1.3 Repeatability-study participants (Study IV) 
At Helsinki University Hospital, 20 subjects with previously diagnosed COPD were 
recruited from the outpatient department of the Division of Respiratory Diseases and from 
the Research Unit for Pulmonary Diseases. All had FEV1 < 80% of predicted (Viljanen et 
al. 1982), and a ratio of FEV1 to FVC under 0.7, and all were ex-smokers with a smoking 
history of ≥ 20 pack years who had stopped smoking at least one year previously. They 
were clinically stable, with no changes in their medication during the preceding 4 weeks 
with the exception of SABA, which were withheld for 12 hours prior to the measurements. 
From among hospital staff and their relatives we recruited 20 healthy subjects with no 
history or symptoms of respiratory diseases. These were either life-time nonsmokers or 
had smoked a maximum of 5 pack-years, but had stopped smoking at least 5 years 
previously. All subjects had been free of respiratory infections for the preceding 4 weeks.  
4.2 Study design 
4.2.1 Association between allergic sensitization and FENO (Study I) 
On the first study day, subjects underwent a structured interview, flow-volume spirometry, 
a bronchodilatation test, and skin prick tests. FENO measurement and a histamine 
challenge, in that order, were performed on the second study day, which was 1 to 14 days 
after the first session. The measurements were carried out in the Laboratory of Clinical 
Physiology (FENO and histamine challenge) and in the Research Unit for Pulmonary 
Diseases of Helsinki University Central Hospital (all other tests) throughout the year from 
May 2001 to March 2003, with the majority of tests performed outside the pollen season. 
4.2.2 Association between FENO and BHR and between FENO, smoking, 
and atopy in subjects with steroid-naive asthma (Studies II and III) 
Flow-volume spirometry, a bronchodilatation test, and skin prick tests were carried out on 
the first study day, and an exercise challenge in the morning of the second study day. 
FENO was measured between 7 and 8 a.m. on the third study day, followed by a histamine 
challenge. The healthy subjects in Study III underwent in the same order the same 
measurements except for the bronchodilatation test, skin prick testing, and the exercise 
challenge. The measurements were performed at the Laboratory of Clinical Physiology of 
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Helsinki University Central Hospital (FENO) and at the Central Military Hospital (all 
other tests) between 1998 and 2002. 
4.2.3 Repeatability of FENO in COPD patients (Study IV) 
FENO was determined three times: at baseline, and at 10 minutes and 24 hours after the 
baseline. Spirometry was carried out on the first study day after the FENO measurements. 
The measurements were performed in the Laboratory of Clinical Physiology (FENO) and 
at the Research Unit for Pulmonary Diseases of Helsinki University Central Hospital 
(spirometry) from April 2006 to November 2008. 
4.3 Clinical methods 
4.3.1 Exhaled nitric oxide measurement 
FENO was measured with a chemiluminescence analyzer (Sievers 270B, Boulder, CO, 
USA). Two-point calibration of the analyzer was performed daily before FENO 
measurements. Expiratory airflow and exhaled volume were measured with 
pneumotachograph (Baby Pneumotachograph, Erich Jaeger GmbH, Wurzburg, Germany) 
simultaneously with FENO in real time. Before the measurement, subjects rinsed their 
mouths with sodium bicarbonate solution (Hartwall Novelle®, Oy Hartwall Ab, Helsinki,   
Finland) to eliminate any nitric oxide produced in the mouth. After inhalation of NO-free 
gas (synthetic NO-free air in Studies I and IV, 100% oxygen in Studies II and III), 
subjects exhaled from total lung capacity with a constant flow rate against a flow resistor 
(Hans Rudolph, Model #7100R, 200 cmH20 l-1s-1, flow range 0-0.1 l/s in Studies I and 
IV, Hans Rudolph, Model #7100R, 100 cmH20/L/s, flow range 0-0.5 L/s in Studies II and 
III) to close the soft palate, thus avoiding any nasal NO contamination. No nose clips were 
used. The subjects maintained the required flow rate with the aid of visual feedback from a 
computer screen. The exhalation procedure was performed according to guidelines valid at 
the time of each study (ATS guidelines 1999 in Studies I and IV, ERS recommendations 
1997 in Studies II and III). In Studies I and IV, the target flow rate was 50 ml/s, and the 
mean flow rate during the time of the NO plateau generation for an acceptable 
measurement was between 45 and 55 ml/s. In Studies II and III, the mean individual 
exhalation flow ranged between 90 and 120 ml/s. In all studies, exhalation lasted for at 
least 10 seconds, and the mean value recorded for analysis was taken from a 3-second 
period from the end-exhaled NO plateau. At least three successive FENO measurements 
were performed, and their mean value recorded for analysis. The acceptable coefficient of 
variation (CoV) of the successive FENO determinations was < 0.15 in Studies I to III and 
≤ 0.1 in Study IV. 
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4.3.2 Skin prick tests 
The skin prick tests were performed with 15 (Study I) or 13 (Studies II and III) common 
aeroallergens. Allergens tested in all three studies included cat, dog, cow, horse, birch, 
timothy, mugwort, the house dust mites Dermatophagoides pteronyssinus and D. farinae, 
and the outdoor moulds Cladosporium and Alternaria. In addition, the storage mites 
Acarus siro and Lepidoglyphus destructor, cockroach, and latex were tested in Study I, 
and cocksfoot, alder, and sheep’s wool in Studies II and III. Histamine dihydrochloride 
(10 mg/ml) served as the positive, and the solvent (glycerol) as the negative control. All 
extracts were provided by ALK, Denmark, except latex, which was provided by 
Stallergenes, France. The tests were carried out by experienced nurses on the volar side of 
the forearm. Reactions were inspected after 15 minutes, and the wheal size was measured 
in millimeters in two directions perpendicular to each other including the longest diameter, 
with their mean recorded as the response. A response of ≥ 3 mm in the presence of the 
expected reactions to the control solutions was regarded as positive (Dreborg 1989). 
Subjects with at least one positive reaction were regarded as skin prick test-positive and 
defined as atopics. Those subjects who did not react to the positive control or reacted to 
the negative control were excluded. Study I also assessed the prick wheal sum (“atopy 
score”), calculated by adding up the mean diameters of each positive reaction (Miles et al. 
1995, Koh et al. 2002). 
4.3.3 Spirometry 
Spirometry was performed with a flow-volume spirometer (SensorMedix Vmax 20C, 
Yorba Linda, CA, USA, in Studies I and IV, and Medikro M904, Kuopio, Finland, in 
Studies II and III). The FVC and FEV1 were determined according to guidelines valid at 
the time of the studies (ATS 1995 for Study I, Quanjer et al. 1993 for Study II and III, and 
Miller et al. 2005 for Study IV). For the bronchodilatation test, 0.4 mg of inhaled 
salbutamol aerosol (Ventoline®, GlaxoSmithKline, Brentford, UK) was administered via 
a spacer (Volumatic®, GlaxoSmithKline). FVC and FEV1 measurements were repeated 
15 minutes after salbutamol administration. The results are expressed as absolute values 
and as percentage of predicted value using published Finnish reference values (Viljanen et 
al. 1982). Prior to the spirometry, SABA were withheld for 4 hours (Study I) or for 12 
hours (Studies II to IV) and LABA for 12 hours (Study I). 
4.3.4 Histamine challenge 
The histamine challenge for assessment of bronchial responsiveness was performed by a 
dosimetric method with controlled tidal breathing (Sovijärvi et al. 1993). Buffered 
histamine diphosphate was administered by an automatic, inhalation-synchronized jet 
nebulizer (Spira Elektro 2, Respiratory Care Center, Hämeenlinna, Finland) in a four-step 
non-cumulative dosage scheme (0.025 mg, 0.1 mg, 0.4 mg, and 1.6 mg). A provocative 
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dose of histamine inducing a 15% decrease in FEV1 (PD15FEV1) was calculated from the 
logarithmically transformed histamine doses by use of linear interpolation or 
extrapolation. If FEV1 did not decrease at least 10% after the maximum dose of 1.6 mg of 
histamine, a PD15FEV1 of 3.2 mg served as the final result. After the final histamine dose, 
patients received 0.2 mg of inhaled salbutamol aerosol (Ventoline®, GlaxoSmithKline, 
Brentford, UK) to relieve bronchoconstriction.   
4.3.5 Exercise challenge 
A standardized 8-minute running test (Karjalainen et al. 1991) was performed outdoors on 
a 150-meter circular track between 9 and 11 AM. Running speed was adjusted by 
monitoring the subjects’ heart rate with a Sport Tester™ PE 3000 heart rate meter (Polar 
Electro Ky, Kempele, Finland). Subjects raised their heart rate to 85% of their predicted 
maximal rate during a 2-minute warm-up and maintained this rate for the remaining 6 
minutes of the exercise. PEF was measured just before the exercise and immediately after, 
and then 5, 10, 20, and 30 minutes after the exercise. Of the three successive PEF 
measurements obtained on each occasion, the highest was recorded for analysis. The 
response to exercise challenge was the maximum percentage fall in PEF (∆PEF%) after 
exercise: % fall in PEF = [(PEF (baseline) – PEF (after)) / (PEF (baseline)] x 100). 
The exercise challenge was conducted outdoors in temperatures ranging from – 17.5 to 
+ 21.4ºC (mean 6.5ºC). Therefore, for all exercise challenges, ∆PEF% was adjusted to a 
temperature of 6.5ºC by use of the regression coefficient (–0.327) between air temperature 
(ºC) and ∆PEF%. This coefficient was obtained by linear regression from similar outdoor 
exercise tests in 1 809 conscripts with similar symptoms (Latvala et al. 2000). Those 
exercise tests took place during the years 1985 to 1998 at temperatures ranging from -25ºC 
to +26ºC.   
4.3.6 Structured interview 
The structured interview was conducted by one of the five trained physicians involved in 
the study, using a questionnaire developed for the FinEsS studies. The questionnaire 
contains 162 questions on general health, recent or past respiratory symptoms, diagnosed 
asthma or other chronic respiratory diseases, provocative factors, and risk factors for 
respiratory diseases, history of cardiovascular diseases or other major diseases, 
medications, and smoking history. This questionnaire is based on one developed and 
validated in the Swedish Obstructive Lung Diseases in Northern Sweden (OLIN) studies 
(Lundbäck et al. 1991, 1993, Torén, et al. 1993). The FinEsS questionnaire has been 
described in detail earlier (Kainu 2008). 
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4.4 Statistical methods 
All statistical analyses were performed with the Statistical Package for Social Sciences 
(SPSS for Windows version 11.0 (Studies I and II) or 15.0 (Studies III and IV); SPSS, 
Chicago, IL, USA). All tests were 2-sided, except the nonparametric ranking for the 
assessment of a 1-tailed 95% upper limit of FENO in Study I, and a p-value of < 0.05 was 
considered significant. Since FENO and PD15FEV1 were not normally distributed, the 
results are expressed as median values and 25 to 75% quartile ranges, and for analyses 
log10 transformation was performed to achieve a near normal distribution. Because each 
study included several statistical aspects to take into consideration, the details are 
described separately by study. 
4.4.1 Study I   
Comparisons of median FENO values between groups were analyzed with the Mann-
Whitney U-test. Comparisons of anthropometric and spirometric variables between atopic 
and nonatopic healthy subjects were performed with an independent samples t-test. Mutual 
correlations between FENO and number of positive skin prick tests, and between FENO 
and total sum of wheal diameters, as well as between FENO and anthropometric variables 
were analyzed with Spearman’s rank correlation coefficients. Since FENO was not 
normally distributed, and normal distribution was not achieved by log-transformation, a 
nonparametric ranking served for assessing the 1-tailed 95% upper limit in the groups. 
4.4.2 Study II 
Differences between anthropometric data, FENO, PD15FEV1, and exercise-induced 
∆PEF% in atopic and nonatopic groups were analyzed with the Mann-Whitney U-test. 
Mutual correlations between FENO, PD15FEV1, and ∆PEF% were analyzed separately in 
the atopic and nonatopic groups with Pearson’s correlation, with 95% confidence intervals 
calculated. Multiple linear regression analyses were undertaken using log (FENO) values 
as outcome variables. The first model evaluated the effect of atopy, asthma, ∆PEF%, and 
log (PD15FEV1). In the second model ∆PEF%, and log (PD15FEV1) were analyzed 
separately for atopic and nonatopic patients. 
4.4.3 Study III 
Multiple comparisons between groups were performed by one-way analysis of variance 
(ANOVA), and p-values corrected for multiple comparisons by the least significant 
difference (LSD) method. If significant differences in baseline characteristics (age, 
weight, height, body mass index) appeared between compared groups, their effect on 
FENO was tested by the analysis of covariance (ANCOVA) method. Possible interactions 
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were tested by two-way ANOVA. Correlations between FENO and spirometric variables 
as well as FENO and hyperreactivity tests were analyzed with Spearman’s rank correlation 
coefficients. 
4.4.4 Study IV 
Bland-Altman plots served to illustrate the repeatability and intra-subject correlation of 
FENO measurements. Intraclass correlation coefficients (ICC) with 95% confidence 
intervals were calculated. Coefficients of variation (CoV) were calculated for intrasession 
and between-session repeatability by dividing the standard deviation (SD) of the 
individual measurements by their mean, and were expressed as percentages. Wilcoxon’s 
pairwise test was used for paired observations. 
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5 RESULTS 
5.1 Association between allergic sensitization and FENO 
Among healthy subjects, median FENO was similar in our 32 skin prick test-positive (13.2 
ppb) and our 41 skin prick test-negative (15.5 ppb) subjects (Figure 4). The 1-tailed 
nonparametric 95% upper limit for FENO in the whole group of healthy asymptomatic 
nonsmoking subjects was 30 ppb, among the skin prick test-positive healthy subjects 31 
ppb, and among skin prick test-negative healthy subjects 29 ppb. 
Among healthy subjects no significant correlation appeared between FENO and degree 
of atopy defined as number of positive reactions (r = -0.138, p = 0.244) or as total sum of 
wheal diameters (calculated by adding up the diameters of each positive reaction (≥ 3 mm) 
(r = -0.135, p = 0.254) (Figure 5). In contrast, among those subjects (n = 175), who were 
excluded because of history, symptoms or signs of respiratory disease, or smoking, a 
statistically significant correlation appeared between FENO and number of positive 
reactions (r = 0.160, p = 0.034) or total sum of wheal diameters (r = 0.178, p = 0.019), as 
well as in the subpopulation of excluded nonsmoking subjects (n = 48) (r = 0.345, p = 
0.016) and (r = 0.343, p = 0.017), respectively (Figure 6). The numbers of positive 
reactions among healthy subjects and excluded subjects were similar (p = 0.25), but mean 
wheal size and total sum of wheal diameters were significantly higher in excluded subjects 
than in healthy subjects (p = 0.005 and 0.047). Of the healthy skin prick test-positive 
subjects, 75% were sensitized only to perennial or seasonal allergens and 25% to both 
groups of allergens, whereas among excluded skin prick test-positive subjects these 
percentages were 57% and 45%. 
 
Figure 4 FENO (flow rate 50 ml/s) in nonsmoking healthy asymptomatic skin prick test (SPT)-
positive (n=32) and -negative (n=41) subjects. Data expressed as medians with 
interquartile range (box) and range (whiskers) excluding an outlier (circle). 
(Reprinted with permission from: Rouhos et al. 2008, Clin Respir J, 2:141-148. 
©Wiley-Blackwell)  
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Figure 5 Correlation between FENO (flow rate 50 ml/s) and number of positive skin prick tests 
(a) and between FENO and total skin prick test wheal sum (calculated by adding the 
diameters of each positive reaction together) (b) in healthy nonsmokers with no signs 
or symptoms of airway disease (n=73). (Reprinted with permission from: Rouhos et 
al.2008, Clin Respir J, 2:141-148. ©Wiley-Blackwell)  
 
  
Figure 6 Correlation between FENO (flow rate 50 ml/s) and number of positive skin prick tests 
(a) and between FENO and total skin prick test wheal sum (calculated by adding the 
diameters of each positive reaction together) (b) in nonsmokers with signs, symptoms 
or history of airway disorder (n=48). 
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5.2 Association between bronchial hyperresponsiveness, atopy 
and FENO 
FENO was significantly higher among all 128 atopic than among all 53 nonatopic 
patients, 21.2 ppb (median) vs. 10.2 ppb, p < 0.001, with 12 ppb being the upper normal 
limit measured by the same method (Ekroos et al. 2000). Among patients with a 
confirmed diagnosis of asthma, FENO was 29.6 ppb among the 68 atopics and 12.4 ppb 
among the 19 nonatopics (p < 0.001). In atopic patients, the mean fall in PEF after 
exercise (EIB) was slightly but significantly more severe, but their PD15FEV1 in histamine 
challenge (HIB) did not differ significantly from that of nonatopics. When only subjects 
with a confirmed diagnosis of asthma were analyzed, no significant difference appeared 
between atopic and nonatopic groups in EIB or HIB (Table 3). A significant correlation 
existed between EIB and HIB in both atopic and nonatopic groups, but the correlation was 
more pronounced in the atopic group (r = -0.48, p < 0.001) than among nonatopic patients 
(r = -0.29, p = 0.035).   
 
 
Table 3. FENO (flow rate 90-120 ml/s), exercise-induced bronchoconstriction and 
histamine-induced bronchoconstriction in young male patients 
All atopic patients 
(n = 128)
Atopic asthmatics 
(n=68)
All nonatopic 
patients (n=53)
Nonatopic 
asthmatics (n=19)
FENO, ppb 21.2 (13.2-44.6)* 29.6 (18.4-52.0)† 10.2 (8.4-14.8) 12.4 (8.5-20.0)
∆PEF% 11.2 (-1.9 - 54.0)** 16.6 (-1.4 - 54.0) 7.1 (-2.1 - 35.5) 12.3 (-2.1 - 35.5)
PD15FEV1, mg 1.0 (0.4-2.5) 0.4 (0.2-1.0) 1.5 (0.5-3.2) 0.4 (0.2-0.7)
PD15FEV1: provocative dose of histamine causing a 15% fall in FEV1 
∆PEF%: maximum percentage fall in PEF after exercise 
PD15FEV1 and FENO expressed as median (25-75 percentiles), ∆PEF% as mean (range)
atopics vs nonatopics: * p < 0.001; ** p < 0.01
atopic asthma vs nonatopic asthma: † p < 0.001  
 
 
 
The multiple linear regression model showed that atopy (p < 0.001), severity of EIB 
(expressed as ∆PEF%) (p < 0.001), and severity of HIB (expressed as log PD15FEV1) (p = 
0.006), all significantly and independently associated with FENO (expressed as 
logFENO). A significant interaction occurred between atopy and severity of EIB as well 
as between atopy and HIB in their relationship with FENO; separate regression models 
were therefore constructed for atopic and nonatopic patients. In these models, EIB and 
HIB associated with FENO in atopic patients, whereas in nonatopic patients, FENO did 
not associate with bronchial hyperresponsiveness measured by either an indirect or direct 
method (Table 4, Figure 7). These associations were similar when only patients with 
confirmed diagnosis of asthma were analyzed. 
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Table 4. Multiple linear regression model with log(FENO) as the dependent variable and 
∆PEF% and log(PD15FEV1) as independent variables in atopic and nonatopic 
patients. (Reprinted with permission from: Rouhos et al.2005, Allergy, 60:1493-
1498. ©Wiley-Blackwell)   
Variable B 95% CI p value B 95% CI p value
∆PEF% 0.029 0.015 to 0.042 < 0.001 0.012 -0.011 to 0.035 0.290
log (PD15FEV1) -0.166 -0.28 to -0.051 0.005 -0.037 -0.180 to 0.105 0.600
B = regression coefficient; CI = confidence interval; ∆PEF%: maximum percentage fall in PEF after 
exercise; PD15FEV1: provocative dose of histamine causing a 15% fall in FEV1 
Adjusted coefficient of determination (R2) for all variables is 0.27 among atopic patients
Atopic patients (n = 128) Nonatopic patients (n = 53)
 
 
    
Figure 7 Association between exercise-induced bronchoconstriction (EIB, % fall in PEF) and 
exhaled nitric oxide (FENO, ppb) in (a) atopic and (b) nonatopic patients. The curve 
is exponentially fitted. Rsq = r2 (coefficient of determination) (Reprinted with 
permission from: Rouhos et al.2005, Allergy; 60:1493-1498. ©Wiley-Blackwell)   
5.3 Influence of smoking and atopy on FENO in asthma 
The total study population of 135 conscripts of Study III comprised 123 men and 12 
women (7 women among the 54 atopic nonsmoking asthmatics, 3 women among the 16 
nonatopic nonsmoking asthmatics, and 2 women among the 16 nonatopic smoking 
asthmatics). Of the 116 asthmatic subjects, 40% were smokers. Based on skin prick tests, 
30 (65%) smoking asthmatics and 54 (77%) nonsmoking asthmatics were atopic.  
Median FENO among smoking asthmatics (13.5 ppb) was significantly higher than in 
smoking (7.3 ppb) and non-smoking (6.7 ppb) healthy controls (p = 0.001, both 
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comparisons). Among nonsmoking asthmatics, FENO was significantly higher (24.0 ppb) 
than among smoking asthmatics (p = 0.002) (Figure 8). Among atopic asthmatics, FENO 
was significantly higher in nonsmoking (29.2 ppb) than in smoking subjects (14.3 ppb) (p 
= 0.002), whereas nonatopic asthmatics showed no difference between those nonsmoking 
(13.1 ppb) and those smoking (12.9 ppb) (p = 0.89) (Figure 9). Further, among nonatopic 
asthmatics, FENO was significantly higher than in healthy controls (p = 0.003), even 
among smoking nonatopic asthmatics (p = 0.01).  
The results of all these comparisons remained unchanged even with the female 
conscripts (n=12) excluded from the analyses. Among atopic asthmatics, 89% of 
nonsmokers and 57% of smokers had FENO levels exceeding 12 ppb – the upper limit 
measured by the same method (Ekroos et al. 2000), whereas among nonatopic asthmatics 
this level was exceeded by 56% of both nonsmokers and smokers.  
No significant correlations appeared between FENO and spirometric variables in any 
of the groups studied. A significant correlation between FENO and the degree of BHR to 
direct and indirect stimuli appeared only among nonsmoking atopic asthmatics (r = -0.41, 
p = 0.003 between FENO and PD15FEV1, and r = 0.40, p = 0.003 between FENO and 
ΔPEF%). 
 
 
Figure 8 FENO (flow rate 90-120 ml/s) in healthy and asthmatic smokers (atopic and 
nonatopic) and nonsmokers (atopic and nonatopic). Data expressed as medians with 
interquartile range (box) and range (whiskers) excluding outliers (circle) and 
extremes (asterisk). (Reprinted with permission from: Rouhos et al.2010, Int Arch 
Allergy Immunol; 152:226-232. ©S. Karger AG, Basel)   
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Figure 9 FENO (flow rate 90-120 ml/s) in atopic and nonatopic steroid-naive asthmatic 
smokers and nonsmokers. Data expressed as medians with interquartile range (box) 
and range (whiskers) excluding outliers (circle) and extremes (asterisk). (Reprinted 
with permission from: Rouhos et al.2010, Int Arch Allergy Immunol; 152:226-232. 
©S. Karger AG, Basel)   
5.4 Repeatability of FENO in COPD 
Of the 20 COPD patients in Study IV, 12 had moderate (GOLD stage 2), 5 had severe 
(GOLD stage 3) and 3 had very severe COPD (GOLD stage 4). One subject (female, 73 
yrs) with stage 4 COPD was unable to perform technically acceptable FENO 
measurements and thus was excluded from the analysis. All 20 healthy subjects were able 
to perform such measurements. 
No significant difference appeared between FENO values at baseline and at +24 h 
either among COPD patients (p = 0.62) or among healthy subjects (p = 0.68). FENO 
values at +10 min measurement (when the subjects did not rinse their mouths with sodium 
bicarbonate) in COPD patients as well as in healthy subjects were slightly but significantly 
higher than at baseline (p = 0.008 and p = 0.002, respectively). Within an interval of 24 
hours, CoV of FENO was 12.4 in COPD patients and 15.9 in healthy subjects. Intrasession 
repeatability for COPD patients and healthy subjects ranged from 5.5 to 6.9%, the 
requirement, according to current guidelines (ATS/ERS 2005), being ≤ 10%. 
Median FENO values for baseline and +24 h measurements, CoV and ICC between 
baseline and +24 h measurements for healthy subjects, for all COPD patients, and 
separately for COPD patients with stage 2 and stage 3-4 disease are shown in Table 5. The 
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repeatability between baseline and +24 h measurements of FENO in COPD patients and in 
healthy subjects is presented by Bland Altman plots, where the mean of baseline and    
+24 h FENO value is plotted against the difference between the FENO values of the two 
respective sessions (Figure 10).  
 
Table 5. Median FENO values (flow rate 50 ml/s) and their short-term variability in the 
groups studied   
FENO baseline (ppb) FENO +24 h (ppb) CoV (%) ICC (95% CI)
Healthy (n=20) 15.2 (10.1-21.6) 14.5 (7.7-22.3) 15.9 0.90 (0.77-0.96)
COPD (n=19) 15.6 (12.8-22.5) 15.7 (11.1-22.8) 12.4 0.88 (0.72-0.95)
GOLD stage 2 (n=12) 18.2 (14.5-25.7) 15.5 (11.1-29.3) 13.7 0.89 (0.65-0.97)
GOLD stage 3-4 (n=7) 13.6 (9.2-18.6) 15.9 (11.0-20.5) 10.5 0.83 (0.37-0.97)
FENO +24 h: FENO measurement 24 h after baseline
CoV: coefficient of variance; ICC: intraclass correlation coefficient; CI: confidence interval 
FENO expressed as medians (25-27% quartiles)
 
 
 
 
 
Figure 10 Day-to-day (24 h) repeatability of FENO presented as Bland-Altman plots in COPD 
patients (a) and in healthy subjects (b). 
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6 DISCUSSION 
6.1 Study populations and methods 
6.1.1 Study populations 
The subjects selected by a randomized procedure from the adult population in Study I 
were thoroughly characterized by objective tests and a detailed structured interview. This 
allowed further selection of nonsmoking healthy subjects with no signs, symptoms, or 
history of airway disorders for assessment of the influence of allergic sensitization per se 
on FENO. The age group of 27 to 61 years represents a relevant adult target group for 
FENO measurements in clinical practice.  
In Studies II and III, the army conscripts are an ideal group for assessment of 
associations between bronchial hyperresponsiveness and FENO. In addition to being 
currently symptomatic and steroid-naive, they formed a homogenous, sufficiently large 
group of subjects of the same age and with no interfering diseases. Since the majority of 
the subjects were males, the influence of gender could not be assessed. Whether these 
young adults with nonatopic asthma represented the typical adult onset phenotype of the 
disease or rather the childhood phenotype of diseases with good prognosis is unclear, and 
follow-up studies should investigate this issue.  
In Study IV, COPD patients represented differing degrees of disease severity, from 
moderate to very severe. Only ex-smokers (defined by the commonly used criterion of 
smoking cessation at least one year earlier) were included in order to avoid any influence 
of current smoking on FENO. These results may thus be inapplicable to current smokers 
with possible smoking-induced variations in FENO, but they reflect the variation caused 
by chronic obstruction per se. In order to obtain a “real-life” population, no subjects with 
comorbidities were excluded if they were clinically stable. This is essential for clinical 
application of these results, as COPD patients frequently have comorbidities (Bourdin et 
al. 2009).  
6.1.2 Methods 
6.1.2.1 FENO measurement 
FENO concentration is dependent on flow rate, with higher flow rates producing lower 
FENO values and vice versa. During the 1990s, development of and research on FENO 
measurement was rapid, with several flow rates used. Because the army conscript study 
began in 1998, FENO measurement in Studies II and III was performed according to that 
suggested in ERS guidelines from 1997 (Kharitonov et al. 1997), except that the flow rate 
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was slightly lower (90-120 ml/s) than suggested in the guidelines (167-250 ml/s). The 
study was already underway by the time of the guideline update, so the flow rate was not 
altered in the middle of the study. The flow rate used resulted in lower FENO 
concentrations than would have been obtained with the currently recommended flow rate 
of 50 ml/s. Since flow rate remained unchanged throughout the study, comparisons 
between FENO concentrations in various groups in Studies II and III are probably not 
markedly affected. FENO measurements in Studies I and IV were performed at the flow 
rate of 50 ml/s, valid since 1999 (ATS 1999). Since this flow rate is identical to that of the 
current guidelines (ATS/ERS 2005), reference material for FENO for the Finnish adult 
population could be obtained from Study I. Because the spirometric maneuver and 
bronchial hyperreactivity tests may temporarily reduce FENO (Silkoff et al. 1999, de 
Gouw et al. 1998), FENO measurements in all studies were performed either before 
spirometry (Study IV) or on a separate study day (Studies I-III). Histamine challenge in 
Studies I to III was performed after FENO measurements, and the exercise challenge one 
day prior to FENO measurement (Studies II and III). The exercise challenge has been 
reported to have no effect on eosinophilic airway inflammation or on airway 
responsiveness (Gavreau et al. 2000, Scollo et al. 2000, El-Halawani et al. 2003).  
6.1.2.2 Skin prick tests 
Allergic sensitization in Studies I to III was assessed by skin prick testing performed by 
trained and experienced nurses according to recommendations of the European Academy 
of Allergology and Immunology (Dreborg 1989), except for single tests performed instead 
of duplicates. The tests included a large number of common aeroallergens relevant to the 
Finnish population (Pallasaho et al. 2006b). In Study I, quantification of skin prick test 
results was also applied by analysis of mean wheal sizes, number of positive reactions, 
and prick wheal sum, calculated by adding up the diameters of each positive reaction 
(Miles et al. 1995, Koh et al. 2002). Many studies have assessed allergic sensitization by 
measuring serum IgE instead of performing skin prick tests. IgE, however, significantly 
varies by gender, age, and smoking, as well as showing considerable overlap in normal 
and atopic ranges (Baldacci et al. 2001). 
6.1.2.3 Assessment of bronchial hyperresponsiveness and lung function 
Bronchial responsiveness was assessed by direct (Studies I to III) and indirect (Studies II 
and III) stimuli. Histamine challenge was performed by a dosimetric method with 
controlled tidal breathing, which is a validated method with good reproducibility 
(Sovijärvi et al. 1993). This method has been in routine use in the laboratory of Clinical 
Physiology of Helsinki University Central Hospital and in the Central Military Hospital 
since the 1990’s. 
The exercise challenge was carried out in the form of a free-running test outdoors. This 
is appropriate for a study population of young adults, and has been part of routine 
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assessment of subjects with suspected asthma in the Central Military Hospital since the 
1980’s. According to the guidelines (Crapo et al. 2000, Joos et al. 2003), a valid test 
requires target exercise intensity to be sustained for 4 to 6 minutes, and to be achieved 
within 4 minutes, in order to avoid the potential refractoriness to exercise-induced 
bronchoconstriction (EIB) induced by prolonging warm-up time. These requirements were 
fulfilled, because the 8-minute free-running test was heart-rate controlled, with its target 
intensity achieved within the first 2 minutes.  
The tests were performed in various weather conditions, so the results were 
temperature-adjusted according to a previously reported method (Latvala et al. 2000). No 
adjustments were made for air humidity, which might have caused some variation. 
Although measurement of FEV1 is recommended for evaluation of EIB severity (Crapo et 
al. 2000, Joos et al. 2003), we performed the evaluation using PEF measurements which 
had been standard at the Central Military Hospital for over 20 years. A decrease in PEF of 
≥ 10% instead of 15% was regarded as diagnostic of asthma in this heart-rate controlled 
exercise challenge. Only 4% of the subjects had their asthma diagnosis based only on a 
PEF decrease of 10 to 14% after exercise challenge.     
Flow-volume spirometry was used in all studies for assessment of lung function and 
was performed according to guidelines valid at the time of the studies. Differences 
between guidelines were, however, only minor (Miller et al. 2005). Results were 
expressed as a percentage of current Finnish reference values (Viljanen et al. 1982). 
6.1.2.4 Structured interview and assessment of smoking status 
In Study I, information from the structured interview served to characterize the subjects. 
Results from the FinEsS study based on the data from this structured interview have 
already appeared (Kotaniemi 2005, Pallasaho 2006a, Kainu 2008). 
Smoking status and smoking history in all four studies was assessed by interview: in 
Study I by a study physician using a structured interview, in Studies II and III upon 
admission to the hospital, with a nurse using open questions, and in Study IV by a study 
physician or a nurse. As the COPD patients in Study IV had already been diagnosed, their 
smoking history was also available from their hospital records.  Even though smoking 
status was not biochemically verified, this assessment can be regarded as reliable, since 
interviewer-assessed smoking status has been reported to yield higher estimates of 
sensitivity and specificity than do self-administered questionnaires, and observational 
studies to show a higher level of sensitivity than do intervention studies (Patrick et al. 
1994). 
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6.2 Discussion of the main results 
6.2.1 Allergic sensitization without signs of airway disorders does not 
increase FENO 
We observed similar levels of FENO in skin prick test-positive and -negative healthy 
asymptomatic nonsmoking adults with no signs, symptoms, or history of airway disorders, 
indicating that atopic sensitization per se does not elevate FENO. A similar finding was 
reported in a slightly smaller group of 28 skin prick test-positive and 22 skin prick test-
negative healthy subjects who had no symptoms or signs of airway disease, no signs of 
airway obstruction in spirometry, and no bronchial hyperresponsiveness in methacholine 
challenge (Berlyne et al. 2000). Such results are not necessarily contradictory to previous 
findings of elevated FENO in atopic compared to nonatopic subjects, since those studies 
have included subjects with increased bronchial hyperresponsiveness, previous symptoms, 
or even a previous diagnosis of asthma (Horváth & Barnes 1999, Franklin et al. 2004, Olin 
et al. 2006). Although those subjects were asymptomatic at the time of the study, such 
airway disorders may influence assessment of the relationship between FENO and allergic 
sensitization; subclinical airway inflammation may be present and be reflected in FENO 
levels. Higher FENO has appeared in atopic asthmatics in clinical remission — defined  as 
complete absence of symptoms without any medication during the preceding year — than  
in healthy subjects, whereas FENO levels were similar with those of subjects with steroid-
naive mild atopic asthma (van den Toorn et al. 2000). Repeated low-dose allergen 
challenge in asymptomatic subjects with mild atopic asthma has resulted in an 
asymptomatic increase in airway inflammation measured by FENO and by several indices 
in sputum samples (de Kluijver et al. 2002); higher FENO has appeared in asthmatics both 
sensitized and exposed to a relevant allergen than in those sensitized but not exposed 
(Simpson et al. 1999). A recent longitudinal study with a 4-year follow up of 1 506 
subjects showed that baseline FENO > 30 ppb in an asymptomatic subject was associated 
with increased risk for wheeze during follow-up (Olin et al. 2010). This result further 
supports the hypothesis that increased FENO in an asymptomatic subject is related to 
subclinical eosinophilic airway inflammation.  
Among healthy nonsmoking subjects, we found no significant correlation between 
FENO and degree of atopy defined either as number of positive reactions or as total sum 
of wheal diameters. This is not contrary to previous findings that a significant correlation 
appears between FENO and number of positive skin prick tests, since those studies 
included subjects with physician-diagnosed asthma and even recent respiratory symptoms 
suggesting asthma (Ho et al. 2000, Franklin et al. 2004). Similarly, in the present study, a 
positive correlation between FENO and degree of atopy did appear among subjects with 
history, symptoms, or signs of an airway disorder. 
The findings of this study suggest that the same reference range can be applied to both 
skin prick test-positive and -negative adult subjects. The largest study defining reference 
values of FENO for adults suggests that FENO be adjusted according to height and age, 
whereas atopic status, defined as increased serum IgE levels, was of minor importance, 
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suggesting the same upper normal limits (24-53 ppb, depending on age and height) for 
both atopic and nonatopic healthy nonsmoking subjects (Olin et al. 2007). 
6.2.2. Association between FENO and bronchial hyperresponsiveness 
appears only in atopics 
Studies addressing the association between eosinophilic airway inflammation and 
bronchial hyperresponsiveness have yielded conflicting results. The association between 
these components of airway pathology is complex. Bronchial responsiveness itself is 
thought to consist of a variable component reflecting the current inflammatory status and 
of a more persistent component reflecting structural changes of airway remodeling. These 
features may be influenced by genetic background, by atopic constitution, and by duration 
of disease. Intensity of airway inflammation is reflected to some extent in symptom status, 
with more intense inflammation being more likely in a subject with current respiratory 
symptoms than in an asymptomatic subject with mild, intermittent disease, although 
symptom perception varies considerably. In addition, steroid treatment, influencing both 
bronchial responsiveness and airway inflammation, affects the correlation between these 
aspects. Smoking influences both hyperresponsiveness and the composition of airway 
inflammation, and although after smoking cessation many changes are reversible, 
permanent influences may remain (Willemse et al. 2004a). Methods for assessment of 
bronchial hyperresponsiveness also influence the reported associations between airway 
inflammation and bronchial hyperresponsiveness, challenges by indirect stimuli being 
more likely to reflect airway inflammation than would challenges by direct stimuli (Joos et 
al. 2003).  
The present study included both atopic and nonatopic subjects, with the study 
population’s being very homogenous in other aspects: all being nonsmokers, steroid-
naive, and with current respiratory symptoms suggesting asthma. We also included 
patients not fulfilling the functional criteria of asthma, in order to obtain a wider range of 
variety in airway inflammation and BHR. We found a statistically significant correlation 
between airway inflammation (assessed by FENO) and severity of bronchial 
hyperresponsiveness to indirect stimulus (exercise) among atopic subjects but not among 
nonatopics. A significant correlation between FENO and BHR to a direct stimulus, 
histamine, also appeared among atopics but not among nonatopics. These results did not 
even change when only those subjects with an unequivocal diagnosis of asthma were 
included. Although median FENO was higher among atopic subjects, increased levels of 
FENO appeared also among nonatopic subjects. No correlation, however, existed between 
FENO and bronchial hyperresponsiveness (EIB or HIB) among nonatopic subjects, 
despite the fact that almost 40% of them showed elevated FENO. 
We also found EIB to be slightly but significantly more pronounced in atopic than in 
nonatopic patients despite similar reactivity in histamine challenge in these groups. 
Presence of atopy seems to facilitate the development of exercise-induced airway 
hyperresponsiveness. In a group of mainly atopic asthmatics, a significant correlation 
appeared between atopy score and EIB severity (Koh et al. 2002), and EIB severity has 
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also been shown to correlate with markers of eosinophilic airway inflammation in sputum 
and blood (Yoshikawa et al. 1998). Atopic patients have also been reported to be more 
reactive to another indirect stimulus, AMP, than are nonatopic patients (Lúdvíksdóttir et 
al. 2000). No reports were available comparing the association between FENO and 
bronchial responsiveness to exercise between atopics and nonatopics. A significant 
association emerged between baseline FENO and EIB in 24 asthmatic children, most of 
whom were atopic (Scollo et al. 2000). El-Halawani and co-workers (2003) demonstrated 
the role of FENO as a predictor of exercise-induced bronchoconstriction in subjects with 
suspected diagnosis of EIB, but their study did not verify atopic status by objective tests. 
In concordance with our results, a recent pediatric study found increased FENO levels in 
both atopic and nonatopic wheezy children with EIB, but a significant correlation between 
FENO and EIB only among atopic subjects (Malmberg et al. 2009).  
Grönke and co-workers (2002) found their correlation between FENO and BHR 
methacholine to depend on duration of asthma, with a significant correlation for those with 
shorter duration of the disease. Further evidence suggesting that the influence of disease 
duration may be essential is provided by a recent study involving 267 asthmatic children 
and adolescents, mainly atopics, in whom BHR to a direct stimulus, acetylcholine, 
associated significantly with airway inflammation, assessed by FENO, in children aged 5-
11 years; among adolescents (12-20 yrs), however, BHR associated with structural 
changes, and the association between BHR and FENO was weaker (Motomura et al. 
2009). In contrast to these findings, Zietkowski and co-workers (2006) reported a 
significant correlation between FENO and BRH to histamine in both atopic and nonatopic 
subjects in a study population of 101 nonsmoking steroid-naive asthmatics older (mean 
age 32-40 yrs) than were our participants (mean age 20). Atopic sensitization was assessed 
by skin prick tests as in our study, but no criterion for positive response was mentioned, 
and BHR to histamine was expressed as PC20FEV1, in contrast to our PD15FEV1. 
6.2.3 Smoking attenuates increase in FENO only in atopic asthma 
Smoking is known to alter the composition of asthmatic airway inflammation. Compared 
to figures for asthmatic nonsmokers, the proportion of eosinophils in smokers is lower 
(Chalmers et al. 2001, Broekma et al. 2009), and number of neutrophils is higher 
(Chalmers et al. 2001). Expression of IL-8, a potent neutrophil attractant, is higher in 
asthmatic smokers than in nonsmokers (St-Laurent et al. 2008). IL-8 correlates positively 
with number of neutrophils in sputum, and increases significantly with increasing pack-
years (Chalmers et al. 2001). An increased number of neutrophils correlates inversely with 
FENO (Rytilä et al. 2006). Smoking is also known to reduce FENO by several 
mechanisms: by reduction in cytokine-induced NO-production, iNOS protein, and iNOS 
mRNA, or by smoke-induced toxic damage to NO-producing epithelial cells, or by capture 
of NO from the airways by peroxynitrite formation caused by reactive oxygen species in 
cigarette smoke (Hoyt et al. 2003, Horváth et al. 2004, Wei et al. 2005).  
To our knowledge, the present study was the first to assess whether this influence of 
smoking on FENO differs between those with atopic and nonatopic steroid-naive asthma. 
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Studies addressing the influence of smoking on FENO in asthmatics have either included 
only atopic asthmatics (Horváth et al. 2004) or have not assessed their atopic status 
(Verleden et al. 1999). One study that did assess both atopic (n=65) and nonatopic (n=33) 
asthmatics found increased FENO in atopic and nonatopic steroid-naive asthmatic never-
smokers, but detected no difference from non-asthmatics when current- and ex-smokers 
were included (Malinovschi et al. 2009). No comparison of FENO between atopic and 
nonatopic smokers was performed, and the number of smokers within groups remained 
unreported. The present study was the first to report attenuation of FENO formation only 
in atopic but not in nonatopic smokers with steroid-naive asthma. This finding may result 
from differences in the mechanisms of FENO formation as well as in the sensitivity of 
these mechanisms to smoking in atopic and nonatopic asthma, and demands further study. 
Since smoking reduces FENO, it may compromise the diagnostic value of FENO in 
asthmatic smokers. Although current guidelines for FENO measurement state that 
smokers with asthma do have elevated FENO (ATS/ERS 2005), data supporting this 
conclusion are very limited. As smoking prevalence among adult asthmatics is reported to 
be at the same level as among the general population (Pietinalho et al. 2009) and as 
reference values are based on levels in nonsmokers (Olin et al. 2007), it is essential to 
know whether FENO in steroid-naive asthmatic smokers differs significantly from FENO 
in healthy nonsmokers in order to evaluate the usefulness of FENO measurement in 
distinguishing airway inflammation in smokers with respiratory symptoms. Horváth and 
co-workers (2004) found, among 22 steroid-naive atopic asthmatic smokers, higher FENO 
than in healthy smokers but did not report any comparison to healthy nonsmokers. Study 
by Verleden and co-workers (1999) reported higher FENO among 13 steroid-naive 
asthmatic smokers than among healthy smokers, but no difference when compared to 
healthy nonsmokers. In the present study, FENO among asthmatic smokers, even among 
nonatopic subjects, was significantly higher than FENO among healthy subjects, 
suggesting that FENO measurement may prove useful in assessment of asthmatic airway 
inflammation in young adult smokers. 
Whether FENO in smokers with steroid-naive asthma exceeds the levels in healthy 
subjects eventually depends on the balance between FENO-producing eosinophilic 
inflammation and the FENO-reducing effect of smoking. This balance may be affected by 
age and by length of smoking history. In studies reporting lower FENO in healthy and 
steroid-naïve asthmatic smokers compared to their nonsmoking counterparts, subjects’ 
mean ages have ranged from 29 to 33 years (Horváth et al. 2004) to 53 to 64 years (Rytilä 
et al. 2006). Sundy and co-workers (2007) reported an age-related decline in FENO 
among smokers, and found a significant difference in FENO between healthy smokers and 
nonsmokers in the age group of 21 to 40 years, whereas no difference appeared in those 
aged 18 to 20, corresponding to the recruits in the present study. Smoking status of the 
subjects in Sundy’s study was verified by measurement of serum cotinine, and an inverse 
correlation appeared between serum cotinine and FENO. Accordingly, other studies have 
reported a negative correlation between FENO and number of pack-years (Persson et al. 
1994, Kharitonov et al. 1995a, Corradi et al. 1999).  
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6.2.4 Repeatability of FENO in COPD patients and in healthy subjects is 
equally good 
The rationale for measuring FENO in COPD patients is based on the association reported 
between increased FENO or sputum eosinophilia and response to steroid treatment (Fabbri 
et al. 2003, Leigh et al. 2006, Kunisaki et al. 2008, Lehtimäki et al. 2010), and thus on the 
potential for FENO measurement in identifying potential steroid responders. Prior to 
assessment of the magnitude of any significant change in FENO in response to therapy, 
however, the repeatability of FENO measurements in chronically obstructed patients 
needs study. Severe obstruction in particular may impair the subject’s ability to maintain 
the required flow or impair the diffusion of NO into the exhaled air due to collapse of the 
bronchioles during exhalation; this would influence the repeatability of FENO 
measurement.  
The present study demonstrated that the repeatability of FENO between successive 
days in COPD patients is equal to that in healthy subjects. A FENO CoV of 12.4% in our 
COPD patients is in agreement with the figure Bhowmik and co-workers (2005) reported: 
a CoV of 13.1% for the short-term repeatability of FENO in a group of 79 patients with 
moderate to severe COPD, although their flow rate for the FENO measurements (5 l/min) 
differed from current recommendations (ATS/ERS 2005), and they mentioned no exact 
interval for repeated measurements. Another study assessed day-to-day variation as well 
as diurnal variation in FENO in 8 COPD patients with stage 2 disease as part of a larger 
study of 81 subjects (nonsmokers and smokers with or without airway obstruction); they 
used a multiple flow technique and reported a high degree of reproducibility (ICC 0.993 
for a flow rate of 50 ml/s) in FENO measurements for the whole study group, and 
concluded that their results are applicable for COPD of differing severity (Brindicci et al. 
2008). According to the ATS/ERS guidelines (2005), for acceptable FENO measurement, 
constant expiratory flow is required to continue for at least 6 seconds. This requirement 
might not be easy for patients with severe airway obstruction to fulfill, thus the good 
repeatability of FENO measurements reported in healthy subjects or asthma patients 
(Ekroos et al. 2000, Ekroos et al. 2002, Kharitonov et al. 2003) cannot be directly applied 
to COPD patients.  
In spirometry, of our 20 COPD patients in the present study, 8 had severe or very 
severe airway obstruction. Only one of these 8 was unable to maintain the flow rate 
required to produce repeated FENO recordings fulfilling requirements for an acceptable 
measurement. Bhowmik and co-workers (2005) reported that in a sample of 98 patients 
with airflow obstruction of various degrees, 19 subjects were unable to perform acceptable 
measurements. Those subjects were older (mean age 71) and had a lower FEV1 (mean 
0.84 liters) than did those capable of producing technically acceptable measurements. The 
COPD patients and healthy subjects in our study were not age- or gender-matched: The 
healthy subjects were more often female and younger than the COPD patients. 
Furthermore, we also included COPD patients with comorbidities, representing the usual 
real-life situation. Despite these inequalities, the older disabled subjects with airflow 
obstruction performed FENO measurements as well as did the younger healthy ones. 
Because only ex-smokers were included in our study in order to avoid the influence of 
 
 
 
 
65
current smoking on FENO, the results are thus not applicable to COPD patients who 
smoke, and further studies are needed in that patient group. 
Our results suggest that a change in FENO exceeding 24% is likely to reflect a 
measurable change in the inflammatory process in COPD. A recent study measuring 
FENO (flow rate 50 ml/s) once a month over a period of one year in 59 patients with 
COPD (mean age 66 years and mean GOLD stage 2.6) found a significant correlation 
between individual exacerbation rate and FENO CoV; patients with a FENO CoV of        
> 40% during the year reported a two-fold increase in exacerbation rate over that of 
patients with a FENO CoV of < 40% (de Laurentiis et al. 2008). The design of our study 
does not permit conclusions about clinically significant changes.  
Because FENO measured by the conventional technique reflects airway inflammation 
mainly in the larger airways, it thus may not fully represent the more peripheral 
inflammation present in COPD. NO production from the more peripheral airways can be 
better detected by a technique utilizing multiple flow rates. This peripheral component of 
FENO has been shown to be insensitive to steroid treatment, however, and thus may be 
inapplicable when the purpose of FENO measurement is to identify possible steroid 
responders. A high level of bronchial NO flux has been reported to relate to symptom 
relief and improvement in FEV1 after steroid treatment, whereas no such association has 
been detectable in relation to alveolar NO (Lehtimäki et al. 2010). 
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7 CONCLUSIONS 
In nonsmoking healthy subjects with no signs, symptoms, or history of chronic or 
recurrent airway diseases allergic sensitization per se does not influence FENO levels; this 
supports the view that elevated FENO is not just a feature of atopy, but indicates NO-
producing inflammation in the airways related to airway disease. The upper normal limit 
of FENO was found to be 30 ppb in both skin prick test-positive and -negative subjects. 
 
FENO was associated with bronchial hyperresponsiveness to both direct (histamine) and 
indirect (exercise) stimuli in atopic but not in nonatopic nonsmoking steroid-naive 
subjects with current asthmatic symptoms. In both groups, a significant correlation 
appeared between histamine- and exercise-induced bronchoconstriction, but this 
correlation was more pronounced among the atopic subjects. These findings support the 
view that the pathogenesis of bronchial hyperresponsiveness in atopic asthma is strongly 
involved in airway inflammation reflected by FENO, and they suggest that in nonatopic 
asthma other mechanisms may dominate or coexist in the development of bronchial 
hyperresponsiveness. 
 
Smoking attenuated the increase in FENO in atopic but not in nonatopic steroid-naive 
symptomatic asthma. This finding suggests differences in the mechanisms of FENO 
formation as well as in the sensitivity of these mechanisms to smoking in atopic and 
nonatopic asthma. Compared to healthy subjects, FENO was elevated in both smoking and 
nonsmoking subjects with steroid-naive asthma regardless of atopic status, suggesting that 
FENO measurements may be useful in assessing airway inflammation also in young adult 
smokers. 
 
The short-term repeatability of FENO in COPD patients and in healthy subjects was 
equally good, although subjects with very severe disease may have difficulties in 
maintaining the required flow rate. Change in FENO exceeding 24% is likely to reflect a 
minimum measurable change in the NO-associated inflammatory process in COPD. 
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